---

THE ELECTRON TRANSPORT CHAIN (ETC) — A COMPREHENSIVE TREATISE

---

TABLE OF CONTENTS

1. Introduction & Overview
2. Location and Structural Organization
3. Historical Background
4. Thermodynamic Basis
5. Components of the ETC
6. Complex I (NADH: Ubiquinone Oxidoreductase)
7. Complex II (Succinate: Ubiquinone Oxidoreductase)
8. Ubiquinone (Coenzyme Q)
9. Complex III (Ubiquinol: Cytochrome c Oxidoreductase)
10. Cytochrome c
11. Complex IV (Cytochrome c Oxidase)
12. Complex V (ATP Synthase) — Oxidative Phosphorylation
13. The Proton Motive Force
14. Chemiosmotic Hypothesis
15. P/O Ratios and ATP Yield
16. Shuttle Systems
17. Inhibitors of ETC
18. Uncouplers of ETC
19. Regulation of ETC
20. Reactive Oxygen Species (ROS)
21. Supercomplex Organization (Respirasomes)
22. Clinical Correlations (Comprehensive)
23. Summary Tables

---

1. INTRODUCTION & OVERVIEW

Key Concepts:

• Oxidation = loss of electrons
• Reduction = gain of electrons
• Electrons flow from carriers with more negative (lower) reduction potential to carriers with more positive (higher) reduction potential
• The overall reaction:

NADH + H⁺ + ½O₂ → NAD⁺ + H₂O (ΔG°' = −220 kJ/mol = −52.6 kcal/mol)

FADH₂ + ½O₂ → FAD + H₂O (ΔG°' = −152 kJ/mol = −36.4 kcal/mol)

---

2. LOCATION AND STRUCTURAL ORGANIZATION

2.1 Mitochondrial Anatomy

2.2 Cardiolipin

• Diphosphatidylglycerol — a unique phospholipid found almost exclusively in the IMM
• Contains 4 fatty acid chains (usually linoleic acid)
• Essential for the function of Complex III, Complex IV, and ATP synthase
• Provides structural support and maintains the impermeability of the IMM to protons

🔴 CLINICAL: Barth Syndrome

• X-linked recessive disorder
• Mutation in the tafazzin gene (TAZ) on Xq28
• Tafazzin is a transacylase required for cardiolipin remodeling
• Results in abnormal cardiolipin → impaired ETC function
• Features: dilated cardiomyopathy, skeletal myopathy, neutropenia, 3-methylglutaconic aciduria, growth retardation
• Predominantly affects males

2.3 Mitochondrial DNA (mtDNA)

• Circular, double-stranded DNA — 16,569 base pairs
• Encodes 37 genes: 13 polypeptides (all ETC/ATP synthase subunits), 22 tRNAs, 2 rRNAs
• Maternal inheritance (mitochondria come from the ovum)
• No histones, limited repair mechanisms → high mutation rate (~10x nuclear DNA)
• Heteroplasmy: a cell can contain a mixture of normal and mutant mtDNA
• Threshold effect: disease manifests when the proportion of mutant mtDNA exceeds a critical threshold

🔴 CLINICAL: Mitochondrial inheritance patterns

• All children of an affected mother may be affected (but variable expressivity due to heteroplasmy)
• An affected father CANNOT transmit the disease
• Tissues with high energy demands (brain, heart, skeletal muscle, retina, kidney) are most affected → explains the clinical phenotype of mitochondrial diseases

---

3. HISTORICAL BACKGROUND

---

4. THERMODYNAMIC BASIS

4.1 Standard Reduction Potential (E°')

4.2 Free Energy Relationship

• n = number of electrons transferred
• F = Faraday constant (96,485 J/V·mol = 23.06 kcal/V·mol)
• ΔE°' = E°'(acceptor) − E°'(donor)

4.3 Sites of Sufficient Free Energy for ATP Synthesis

1. Complex I: NADH → CoQ (ΔE = 0.36 V → ΔG = −69.5 kJ/mol)
2. Complex III: CoQH₂ → Cytochrome c (ΔE = 0.21 V → ΔG = −40.5 kJ/mol)
3. Complex IV: Cytochrome c → O₂ (ΔE = 0.57 V → ΔG = −110 kJ/mol)

---

5. COMPONENTS OF THE ETC — ELECTRON CARRIERS

5.1 Types of Electron Carriers

5.2 Flavin Nucleotides (FMN and FAD)

• Derived from Riboflavin (Vitamin B₂)
• Can accept 1 or 2 electrons (can form a semiquinone radical intermediate)
• FMN is the first electron acceptor in Complex I
• FAD is the prosthetic group in Complex II (succinate dehydrogenase)

5.3 Iron-Sulfur Clusters

• Also called non-heme iron proteins
• Contain iron atoms coordinated with inorganic sulfide (S²⁻) and/or cysteine sulfur from the protein
• Types:
  • [2Fe-2S] — Rieske center in Complex III (unique: one Fe coordinated by 2 histidines)
  • [4Fe-4S] — most common, found in Complexes I, II, III
  • [3Fe-4S] — found in Complex II
• Transfer only 1 electron at a time despite having multiple iron atoms
• The most complex arrangement is in Complex I: contains 8 Fe-S clusters forming an electron "wire" ~95 Å long

5.4 Heme Groups and Cytochromes

5.5 Copper Centers

• CuA in Complex IV: dinuclear copper center; first electron acceptor from cytochrome c
• CuB in Complex IV: paired with heme a₃ in the binuclear center; directly involved in O₂ binding and reduction

---

6. COMPLEX I — NADH:UBIQUINONE OXIDOREDUCTASE (EC 1.6.5.3)

6.1 Structure

• Largest respiratory complex
• ~1,000 kDa (1 MDa) in mammals
• 45 subunits in mammals (7 encoded by mtDNA: ND1–ND6, ND4L; 38 nuclear-encoded)
• Shaped like an "L" or a boot:
  • Hydrophilic arm (peripheral arm): projects into the matrix; contains FMN and all Fe-S clusters
  • Hydrophobic arm (membrane arm): embedded in the IMM; contains the proton-pumping machinery
• Contains:
  • 1 FMN (flavin mononucleotide)
  • 8 iron-sulfur clusters: N1a [2Fe-2S], N1b [2Fe-2S], N2 [4Fe-4S], N3 [4Fe-4S], N4 [4Fe-4S], N5 [4Fe-4S], N6a [4Fe-4S], N6b [4Fe-4S]
  • The Fe-S clusters form a ~95 Å electron transfer wire

6.2 Mechanism

1. NADH binds to the hydrophilic arm and donates 2 electrons as a hydride ion (H⁻) to FMN → FMNH₂
2. FMNH₂ passes electrons one at a time through the chain of 8 Fe-S clusters
3. The terminal Fe-S cluster N2 (highest potential in the chain) donates electrons to ubiquinone (CoQ) bound at the ubiquinone-binding site at the junction of the two arms
4. CoQ is reduced: Q → QH⁻ (semiquinone) → QH₂ (ubiquinol)
5. The energy released drives conformational changes in the membrane arm that translocate 4 H⁺ from the matrix to the IMS

6.3 Proton Pumping Mechanism

• The membrane arm contains three antiporter-like subunits (ND2, ND4, ND5) each pumping 1 H⁺
• A fourth proton is pumped at the junction/interface near the ubiquinone-binding site (ND1/ND6 region)
• Total: 4 H⁺ pumped per NADH (per 2 electrons)
• The mechanism involves a long-range conformational coupling — a "piston-like" mechanism transmitted through a long amphipathic helix connecting the antiporter subunits

6.4 Overall Reaction

NADH + H⁺ + Q + 4H⁺(matrix) → NAD⁺ + QH₂ + 4H⁺(IMS)

6.5 Inhibitors of Complex I

🔴 CLINICAL: Rotenone and Parkinson's Disease

• Chronic rotenone exposure in animal models produces Parkinsonism including selective dopaminergic neuron death and Lewy body-like inclusions
• Dopaminergic neurons in the substantia nigra pars compacta are especially vulnerable due to high energy demands and high oxidative stress
• Epidemiological studies link pesticide exposure (rotenone, paraquat) to increased Parkinson's disease risk

🔴 CLINICAL: MPTP Toxicity (Drug-induced Parkinsonism)

• MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a contaminant of synthetic heroin ("designer drug")
• MPTP crosses the blood-brain barrier → taken up by astrocytes → converted to MPP⁺ by MAO-B (monoamine oxidase B)
• MPP⁺ is selectively taken up by dopaminergic neurons via the dopamine transporter (DAT)
• MPP⁺ inhibits Complex I → ATP depletion, ROS generation → selective death of dopaminergic neurons
• Produces acute, irreversible Parkinsonism
• This discovery was pivotal in understanding Parkinson's disease pathogenesis
• Treatment: L-DOPA, dopamine agonists (same as idiopathic Parkinson's)
• Prevention: MAO-B inhibitors (selegiline/rasagiline) can block MPTP → MPP⁺ conversion

🔴 CLINICAL: Leber's Hereditary Optic Neuropathy (LHON)

• Mitochondrial inheritance (maternal)
• Caused by point mutations in mtDNA genes encoding Complex I subunits
• Most common mutations: m.11778G>A (ND4, ~70% of cases), m.3460G>A (ND1), m.14484T>C (ND6)
• Presents in young adults (15-35 years), more commonly in males (male:female = 4:1, suggesting nuclear modifier genes like X-linked factors)
• Acute or subacute painless bilateral central vision loss (sequential, one eye then the other within weeks to months)
• Loss of central vision with centrocecal scotoma (central blind spot)
• Optic disc pseudoedema, peripapillary telangiectatic microangiopathy (does NOT leak on fluorescein angiography)
• Eventually → optic atrophy
• Retinal ganglion cells (especially the papillomacular bundle) are selectively vulnerable
• No consistently effective treatment; idebenone (CoQ analog) may have some benefit, especially in early stages
• Variable penetrance due to heteroplasmy
• Smoking and alcohol use may trigger/worsen the disease (environmental factors)

🔴 CLINICAL: Complex I Deficiency

• Most common cause of mitochondrial disease in children
• Can be caused by mutations in any of the 45 structural genes (7 mtDNA, 38 nuclear) or assembly factor genes
• Clinical spectrum:
  • Leigh syndrome (subacute necrotizing encephalomyelopathy) — most severe
  • MELAS-like syndrome
  • Neonatal lactic acidosis
  • Hypertrophic cardiomyopathy
  • Leukodystrophy
• Lab findings: elevated lactate, elevated lactate:pyruvate ratio (>20:1), elevated alanine

---

7. COMPLEX II — SUCCINATE:UBIQUINONE OXIDOREDUCTASE (EC 1.3.5.1)

7.1 Structure

• Smallest respiratory complex: ~124 kDa
• 4 subunits — ALL nuclear-encoded (the ONLY ETC complex entirely nuclear-encoded)
  • SDHA: flavoprotein subunit; contains covalently bound FAD and the succinate-binding site
  • SDHB: iron-sulfur protein; contains three Fe-S clusters: [2Fe-2S], [4Fe-4S], [3Fe-4S]
  • SDHC and SDHD: membrane-anchor subunits; contain heme b (not involved in electron transfer — may serve in ROS protection) and the ubiquinone-binding site
• Part of both the TCA cycle (as succinate dehydrogenase, enzyme #6) and the ETC

7.2 Mechanism

1. Succinate is oxidized to fumarate (trans double bond) at the SDHA subunit
2. FAD is reduced to FADH₂ (covalently bound, does NOT dissociate)
3. Electrons pass through the three Fe-S clusters in SDHB: [2Fe-2S] → [4Fe-4S] → [3Fe-4S]
4. Electrons are donated to ubiquinone (CoQ) at the Q-binding site in SDHC/SDHD → ubiquinol (QH₂)

7.3 Key Points

• Does NOT pump protons — insufficient free energy change (ΔG ≈ −6 kJ/mol for FAD → CoQ transfer)
• FADH₂ generated here enters the chain at the level of CoQ, bypassing Complex I
• Therefore, FADH₂ from Complex II generates fewer ATP than NADH (1.5 vs. 2.5 ATP)

7.4 Overall Reaction

Succinate + Q → Fumarate + QH₂ (No proton pumping)

7.5 Inhibitors of Complex II

🔴 CLINICAL: Hereditary Paraganglioma-Pheochromocytoma Syndrome

• Germline mutations in SDHB, SDHC, SDHD (and also SDHA, SDHAF2)
• These are tumor suppressor genes (loss-of-function mutations)
• SDH deficiency → accumulation of succinate → inhibits prolyl hydroxylases (PHDs) → stabilization of HIF-1α (Hypoxia-Inducible Factor) → pseudohypoxic signaling → angiogenesis, proliferation
• This is an example of an oncometabolite mechanism
• Clinical manifestations:
  • Paragangliomas (especially head and neck — carotid body tumors)
  • Pheochromocytomas (adrenal medulla)
  • Gastrointestinal stromal tumors (GISTs)
  • Renal cell carcinoma
• SDHB mutations: highest malignancy risk (~30-40% metastatic)
• SDHD mutations: predominantly paternally inherited expression (genomic imprinting)
• Screening: plasma/urine metanephrines and catecholamines
• Immunohistochemistry: loss of SDHB staining in tumor tissue is a marker

🔴 CLINICAL: Carney-Stratakis Syndrome

• Dyad of paraganglioma and gastrointestinal stromal tumor (GIST)
• Due to germline SDH subunit mutations
• Distinct from Carney triad (paraganglioma, GIST, pulmonary chondroma — usually sporadic)

🔴 CLINICAL: 3-Nitropropionic Acid (3-NPA) Toxicity

• Found in moldy sugarcane (Arthrinium saccharicola fungus)
• Irreversibly inhibits Complex II (SDH)
• Causes acute encephalopathy with selective bilateral striatal (basal ganglia) necrosis
• Mimics Huntington's disease pathology
• Used as an experimental model for Huntington's disease

7.6 Other FADH₂-Linked Dehydrogenases

🔴 CLINICAL: Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) / Glutaric Aciduria Type II

• Deficiency of ETF or ETF:ubiquinone oxidoreductase (ETF-QO)
• Impairs electron transfer from multiple FAD-linked dehydrogenases → impaired β-oxidation, branched-chain amino acid oxidation, and others
• Biochemical: elevated multiple acylcarnitines, organic acids (glutaric, ethylmalonic, adipic, suberic acids)
• Clinical: severe neonatal form (with or without congenital anomalies — renal cysts, facial dysmorphism) or milder late-onset form (lipid storage myopathy)
• Treatment: riboflavin (B₂) — many cases are riboflavin-responsive (especially late-onset)

---

8. UBIQUINONE (COENZYME Q / CoQ₁₀)

8.1 Structure

• 2,3-dimethoxy-5-methyl-1,4-benzoquinone with an isoprenoid side chain
• In humans: 10 isoprenoid units (CoQ₁₀ or ubiquinone-50)
• The long hydrophobic tail allows it to dissolve freely in the lipid bilayer of the IMM
• Small, lipid-soluble, mobile electron carrier — NOT a protein

8.2 Redox States

1. Ubiquinone (Q) — fully oxidized
2. Semiquinone radical (QH• or Q•⁻) — partially reduced (one electron)
3. Ubiquinol (QH₂) — fully reduced (two electrons)

8.3 Function

• Collects electrons from Complexes I and II (and other FADH₂-linked dehydrogenases)
• Shuttles electrons to Complex III
• Acts as a mobile electron carrier in the membrane (unlike Fe-S clusters and cytochromes which are protein-bound)
• The CoQ pool contains ~10× more CoQ than Complex III → functions as a mobile electron buffer

8.4 Biosynthesis

• Synthesized endogenously via the mevalonate pathway (same pathway as cholesterol synthesis)
• The benzoquinone ring is derived from tyrosine (or phenylalanine)
• The isoprenoid tail is from the mevalonate pathway (farnesyl pyrophosphate → decaprenyl-PP)

🔴 CLINICAL: CoQ₁₀ Deficiency

• Primary CoQ₁₀ deficiency: autosomal recessive mutations in genes of CoQ₁₀ biosynthetic pathway (COQ2, COQ4, COQ6, COQ7, COQ8A, COQ8B, COQ9, PDSS1, PDSS2)
• Clinical phenotypes:
  • Cerebellar ataxia (most common, often with cerebellar atrophy)
  • Steroid-resistant nephrotic syndrome (especially COQ2, COQ6, COQ8B mutations)
  • Encephalomyopathy
  • Isolated myopathy with ragged red fibers
  • Multisystem infantile form (severe)
• Secondary CoQ₁₀ deficiency: seen in mitochondrial diseases, aging, statin therapy
• Treatment: oral CoQ₁₀ supplementation (one of the few treatable mitochondrial disorders, especially the nephrotic and ataxic forms if treated early)

🔴 CLINICAL: Statins and CoQ₁₀

• Statins (HMG-CoA reductase inhibitors) inhibit the mevalonate pathway
• This reduces not only cholesterol synthesis but also CoQ₁₀ and dolichol synthesis
• May contribute to statin-associated myopathy/myalgia (controversial but biologically plausible)
• Some clinicians recommend CoQ₁₀ supplementation with statin therapy, though evidence is mixed

8.5 CoQ₁₀ as an Antioxidant

• Ubiquinol (QH₂) is a potent lipid-soluble antioxidant
• Protects membrane lipids from peroxidation
• Regenerates vitamin E (α-tocopherol) from its radical form

---

9. COMPLEX III — UBIQUINOL:CYTOCHROME c OXIDOREDUCTASE (EC 1.10.2.2)

9.1 Structure

• ~240 kDa as a functional homodimer (each monomer ~11 subunits in mammals)
• 11 subunits per monomer: 1 mtDNA-encoded (cytochrome b) + 10 nuclear-encoded
• Key catalytic subunits:
  1. Cytochrome b: contains two heme b groups — heme bL (low potential, +0.07 V) and heme bH (high potential, +0.03 V → but higher in the context of electron flow)
  2. Rieske iron-sulfur protein: contains [2Fe-2S] cluster — unique because one Fe is coordinated by 2 histidines instead of cysteines (higher reduction potential: +0.28 V)
  3. Cytochrome c₁: contains heme c₁

9.2 The Q Cycle (Mitchell's Q Cycle)

• Transfers electrons from a 2-electron carrier (QH₂) to a 1-electron carrier (cytochrome c)
• Pumps protons across the membrane
• Effectively doubles the number of protons translocated per QH₂

• Qp site (also called Qo site) — on the P-side (IMS side / positive side) — where QH₂ is oxidized
• Qn site (also called Qi site) — on the N-side (matrix side / negative side) — where Q is reduced

First Half of the Q Cycle:

1. QH₂ binds at the Qp site
2. First electron → Rieske [2Fe-2S] → Cytochrome c₁ → Cytochrome c (which departs as a reduced, mobile carrier)
3. 2 H⁺ are released into the IMS (from QH₂ oxidation)
4. The remaining electron goes to the low-potential pathway: QH• → heme bL → heme bH → reduces Q to Q•⁻ (semiquinone) at the Qn site
5. QH₂ at Qp is now fully oxidized → Q, which leaves

Second Half of the Q Cycle:

1. A second QH₂ binds at the Qp site
2. Again: first electron → Rieske → cyt c₁ → second cytochrome c (reduced and departs)
3. 2 more H⁺ released into IMS
4. Second electron → heme bL → heme bH → reduces the semiquinone (Q•⁻) at Qn to QH₂ (picking up 2 H⁺ from the matrix)
5. This regenerated QH₂ can re-enter the cycle

Net Q Cycle (per pair of electrons reaching cytochrome c):

QH₂ + 2 cyt c (ox) + 2H⁺(matrix) → Q + 2 cyt c (red) + 4H⁺(IMS)

• 2 QH₂ oxidized at Qp
• 1 Q reduced to QH₂ at Qn (net consumption: 1 QH₂)
• 4 H⁺ released to IMS (2 from each QH₂ oxidation at Qp)
• 2 H⁺ consumed from matrix (for QH₂ formation at Qn)
• Net proton translocation: ~4 H⁺ per 2 electrons reaching O₂ via cyt c

9.3 Inhibitors of Complex III

🔴 CLINICAL: Antimycin A and ROS

• When Antimycin A blocks the Qn site, the semiquinone radical (Q•⁻) at the Qp site accumulates
• This semiquinone can donate its electron directly to O₂ → forming superoxide (O₂•⁻)
• Complex III (Qp site) is a major site of mitochondrial ROS production
• Relevant to aging, ischemia-reperfusion injury, and neurodegenerative diseases

🔴 CLINICAL: Complex III Deficiency

• Rare; can be caused by mutations in:
  • Cytochrome b (mtDNA — MT-CYB)
  • BCS1L (assembly factor for Rieske protein)
• BCS1L mutations cause:
  • GRACILE syndrome (Growth Retardation, Aminoaciduria, Cholestasis, Iron overload, Lactic acidosis, Early death) — Finnish heritage
  • Björnstad syndrome (sensorineural deafness + pili torti — twisted hair)
  • Isolated Complex III deficiency with encephalopathy
• MT-CYB mutations: exercise intolerance, myopathy, cardiomyopathy

---

10. CYTOCHROME c

10.1 Structure and Function

• Small (~12.4 kDa), highly conserved, water-soluble protein
• Contains one heme c (covalently attached via thioether bonds to two cysteine residues — -CXXCH- motif)
• Located in the intermembrane space
• Peripheral membrane protein — loosely associated with the outer surface of the IMM (bound by electrostatic interactions with cardiolipin)
• Transfers one electron from Complex III (cyt c₁) → Complex IV (CuA)

10.2 Role in Apoptosis

🔴 CLINICAL: Cytochrome c and Apoptosis (Intrinsic Pathway)

• During intrinsic (mitochondrial) apoptosis:
  1. Pro-apoptotic stimuli (DNA damage, oxidative stress, growth factor withdrawal) activate BH3-only proteins (BID, BIM, BAD, etc.)
  2. These activate BAX and BAK (pro-apoptotic BCL-2 family members)
  3. BAX/BAK oligomerize and form pores in the outer mitochondrial membrane → MOMP (Mitochondrial Outer Membrane Permeabilization)
  4. Cytochrome c is released from the IMS into the cytoplasm
  5. Cytochrome c binds APAF-1 (Apoptotic Protease-Activating Factor 1) → forms the apoptosome (wheel-of-death)
  6. The apoptosome activates Caspase-9 (initiator caspase)
  7. Caspase-9 activates Caspase-3 and Caspase-7 (executioner caspases) → cell death
• Anti-apoptotic proteins (BCL-2, BCL-XL, MCL-1) prevent BAX/BAK activation → prevent cytochrome c release
• Cancer cells often overexpress BCL-2 → resistance to apoptosis
• Venetoclax: BCL-2 inhibitor used in CLL and AML — restores apoptosis by allowing cytochrome c release
• Other proteins released from mitochondria during apoptosis: Smac/DIABLO (inhibits IAPs), AIF (apoptosis-inducing factor — caspase-independent death), endonuclease G, Omi/HtrA2

10.3 Cytochrome c in Evolution

• One of the most conserved proteins in evolution
• Comparing cytochrome c amino acid sequences across species has been used to construct phylogenetic trees
• Human and chimpanzee cytochrome c are identical (100% homology)
• Human and yeast share ~60% identity

---

11. COMPLEX IV — CYTOCHROME c OXIDASE (EC 1.9.3.1)

11.1 Structure

• ~200 kDa as a functional dimer (each monomer: 13 subunits in mammals)
• 3 mtDNA-encoded subunits: COX I, COX II, COX III (catalytic core)
• 10 nuclear-encoded subunits (regulatory/structural)
• Contains 4 redox-active metal centers:
  • CuA center (in COX II): dinuclear copper; first to accept electron from cytochrome c
  • Heme a (in COX I): transfers electron to the binuclear center
  • Heme a₃ (in COX I): part of the binuclear center
  • CuB (in COX I): part of the binuclear center; paired with heme a₃
• Also contains Zn and Mg ions (structural roles)

11.2 Mechanism

1. Cytochrome c (reduced) binds to the IMS face of Complex IV and donates 1 electron to CuA
2. CuA → heme a → binuclear center (heme a₃–CuB)
3. At the binuclear center, O₂ binds (between Fe of heme a₃ and CuB)
4. Four electrons are required to fully reduce O₂:

O₂ + 4 e⁻ + 4 H⁺ (matrix) → 2 H₂O

1. This occurs in a carefully controlled sequence to avoid release of partially reduced oxygen species (superoxide, peroxide)

11.3 Proton Pumping

• 4 "chemical" protons: consumed in the matrix to make H₂O (scalar protons)
• 4 "pumped" protons: translocated from matrix to IMS (vectorial protons)
• Total: 8 H⁺ removed from the matrix per O₂ (4 used for H₂O + 4 pumped)
• But per 2 electrons (from 1 NADH): 2 H⁺ pumped + 2 H⁺ consumed for 1 H₂O

11.4 Overall Reaction

4 cyt c (red) + O₂ + 8H⁺(matrix) → 4 cyt c (ox) + 2H₂O + 4H⁺(IMS)

2 cyt c (red) + ½O₂ + 4H⁺(matrix) → 2 cyt c (ox) + H₂O + 2H⁺(IMS)

11.5 Inhibitors of Complex IV

🔴 CLINICAL: Cyanide Poisoning

• Sources: industrial chemicals (electroplating, mining), smoke inhalation (burning of plastics, wool, silk releases HCN), cyanogenic glycosides (bitter almonds, cassava, apple seeds, cherry pits — contain amygdalin), sodium nitroprusside (releases CN⁻ during prolonged infusion)
• Mechanism: CN⁻ binds Fe³⁺ of cytochrome a₃ → complete inhibition of Complex IV → cells cannot use O₂ → histotoxic/cytotoxic hypoxia
• Classic features:
  • Bright cherry-red skin (venous blood remains oxygenated because cells can't extract O₂)
  • "Bitter almond" breath odor (only 40% of people can detect this — genetically determined)
  • High venous PO₂ (venous blood is almost as oxygenated as arterial → narrow A-V O₂ difference)
  • Lactic acidosis (severe, from anaerobic glycolysis)
  • Rapidly: headache, confusion, seizures, coma, death
  • PaO₂ and O₂ saturation may be normal (pulse oximetry and ABG can be misleadingly normal)
• Lab: elevated lactate, elevated venous O₂ saturation, cyanide levels >0.5 mg/L are toxic, >3 mg/L lethal
• Treatment:
  • 100% oxygen
  • Hydroxocobalamin (Cyanokit®): binds CN⁻ → cyanocobalamin (vitamin B₁₂) → renally excreted. Preferred antidote, especially in smoke inhalation (safe in combined CO/CN poisoning)
  • Sodium thiosulfate: provides sulfur donor for rhodanese (thiosulfate sulfurtransferase) → converts CN⁻ → thiocyanate (SCN⁻) → renally excreted. Slow onset.
  • Sodium nitrite (or amyl nitrite): induces methemoglobinemia → methemoglobin (Fe³⁺) binds CN⁻ → cyanomethemoglobin → draws CN away from cytochrome oxidase. Caution in smoke inhalation (may already have carboxyhemoglobin → further reduces O₂ carrying capacity)
  • Dicobalt edetate (Kelocyanor): used in UK — cobalt directly chelates CN⁻
  • Traditional "Cyanide Antidote Kit": amyl nitrite + sodium nitrite + sodium thiosulfate

🔴 CLINICAL: Carbon Monoxide (CO) Poisoning

• CO binds to:
  1. Hemoglobin (240× greater affinity than O₂) → carboxyhemoglobin (COHb) → leftward shift of O₂-Hb dissociation curve → impaired O₂ delivery
  2. Cytochrome c oxidase (Complex IV) → Fe²⁺ of heme a₃ → histotoxic hypoxia
  3. Myoglobin → impaired muscle O₂ utilization
• Sources: incomplete combustion, house fires, car exhaust, charcoal grills, furnaces
• Findings:
  • Cherry-red skin (due to COHb, but this is a LATE finding — often patients appear pale/cyanotic)
  • Headache (most common early symptom), nausea, confusion, syncope, seizures, coma
  • PaO₂ is NORMAL (dissolved O₂ is unaffected)
  • O₂ saturation by pulse oximetry is FALSELY NORMAL (pulse ox can't distinguish COHb from OxyHb)
  • CO-oximetry is the diagnostic test → directly measures COHb%
  • Normal COHb <3% (non-smokers), <10% (smokers); symptomatic >15-20%; lethal >50-60%
• Treatment:
  • 100% O₂ via non-rebreather mask (reduces COHb half-life from 5 hours → 90 minutes)
  • Hyperbaric oxygen (HBO₂): reduces half-life to ~30 minutes; indicated for COHb >25%, loss of consciousness, neurological symptoms, cardiac ischemia, pregnancy
  • Delayed neuropsychiatric sequelae (DNS): cognitive impairment, personality changes weeks later → may be prevented by HBO₂

🔴 CLINICAL: Hydrogen Sulfide (H₂S) Poisoning

• "Knockdown gas" — toxic in sewer gas, volcanic emissions, petroleum industry
• Mechanism: like cyanide, inhibits Complex IV
• Can cause sudden collapse ("sewer gas asphyxia")
• Rotten egg smell at low concentrations; at high concentrations → olfactory nerve paralysis (can no longer smell it — extremely dangerous)
• Treatment: similar to cyanide → nitrites (to form sulfmethemoglobin), 100% O₂, supportive

🔴 CLINICAL: Nitric Oxide (NO) and Complex IV

• NO is a physiological signaling molecule (vasodilator, neurotransmitter)
• At physiological concentrations: reversibly inhibits Complex IV → may regulate mitochondrial respiration and O₂ utilization
• In excess (sepsis, inflammation → iNOS activation): excessive NO → mitochondrial dysfunction → contributes to septic shock pathophysiology
• NO competes with O₂ at the binuclear center → when O₂ is low, NO inhibition is enhanced → may help redistribute O₂ in tissues (metabolic signaling)

🔴 CLINICAL: Methanol and Formate Toxicity

• Methanol → formaldehyde → formic acid/formate (via alcohol dehydrogenase and aldehyde dehydrogenase)
• Formate inhibits cytochrome c oxidase (Complex IV)
• Causes: metabolic acidosis (high anion gap), blindness (retinal/optic nerve toxicity — retinal ganglion cells are especially vulnerable)
• Treatment: fomepizole (4-methylpyrazole — ADH inhibitor) or ethanol (competitive substrate for ADH), dialysis, folate (enhances formate metabolism to CO₂ and H₂O)

---

12. COMPLEX V — ATP SYNTHASE (F₁F₀-ATP SYNTHASE) (EC 7.1.2.2)

12.1 Overview

• Also called: F₁F₀-ATPase, Complex V
• Not a component of the electron transport chain per se, but is the site of oxidative phosphorylation
• Uses the proton motive force (PMF) generated by Complexes I, III, IV to synthesize ATP from ADP + Pi
• ~600 kDa
• 16 subunits in mammals (2 mtDNA-encoded: ATPase 6 = subunit a, ATPase 8 = subunit A6L)

12.2 Structure

F₁ Component (Soluble, Matrix side — "Factor 1")

• Knob-like structure projecting into the matrix
• Composition: α₃β₃γδε
  • 3 α subunits and 3 β subunits: arranged alternately like segments of an orange
  • Each β subunit contains a catalytic site for ATP synthesis
  • The 3 β subunits exist in 3 different conformations (see binding change mechanism)
  • γ subunit: central stalk/axle; rotates within the α₃β₃ ring; asymmetric → drives conformational changes in β subunits
  • ε subunit: attached to γ; part of the rotor
  • δ subunit: part of the peripheral stalk (in bacterial nomenclature; in mitochondria, the OSCP — Oligomycin Sensitivity Conferring Protein)

F₀ Component (Membrane-embedded — "Factor 0" — "oligomycin-sensitive factor")

• Proton channel
• Composition (in mammals):
  • c-ring: ring of 8-15 c subunits (8 in mammals, 10 in yeast); each c subunit has a proton-binding carboxylate (aspartate or glutamate)
  • a subunit (subunit 6): has two half-channels for proton translocation; stationary
  • b subunit: part of the peripheral/lateral stalk connecting F₀ to F₁ (stator)
  • Additional subunits: d, F6, A6L, e, f, g (structural and regulatory)

Peripheral Stalk (Stator)

• Connects F₁ to F₀ without rotating
• Composed of: b, d, F6, OSCP subunits
• Prevents co-rotation of α₃β₃ with γ → allows the conformational changes in β subunits

12.3 The Rotary Catalysis — Boyer's Binding Change Mechanism

Three Conformations of β Subunits:

1. O (Open): low affinity for substrates; releases ATP
2. L (Loose): binds ADP + Pi loosely
3. T (Tight): catalyzes ATP formation; binds ATP very tightly

Catalytic Cycle (per 120° rotation of γ):

• Step 1: ADP + Pi bind to the L-site (Loose)
• Step 2: γ rotates 120° → L-site converts to T-site (Tight) → ATP is synthesized (essentially a spontaneous condensation reaction when substrates are properly positioned)
• Step 3: The previous T-site converts to O-site (Open) → ATP is released
• Step 4: The previous O-site converts to L-site → ready for new ADP + Pi

12.4 Proton Translocation Through F₀

1. H⁺ from IMS enters the half-channel in the a subunit (inlet half-channel)
2. H⁺ binds to the carboxylate (Asp/Glu) on a c subunit
3. This neutralization allows the c subunit to move into the hydrophobic lipid bilayer environment
4. As the c-ring rotates (driven by the proton gradient), each c subunit eventually reaches the outlet half-channel on the matrix side
5. The H⁺ is released into the matrix

• Depends on the number of c subunits in the ring
• In mammals (8 c subunits): 360°/3 = 120° per ATP; 8 H⁺ per 360° → 8/3 ≈ 2.67 H⁺ per ATP
• Plus 1 H⁺ for the phosphate carrier (Pi/H⁺ symport) → ~3.67 H⁺ per ATP
• Often approximated as ~4 H⁺ per ATP (including phosphate transport)

12.5 ATP/ADP Translocase (Adenine Nucleotide Translocator — ANT)

• Located in IMM
• Antiporter: exchanges ATP⁴⁻ (out to IMS) for ADP³⁻ (in to matrix)
• This exchange is electrogenic — net export of 1 negative charge → driven by the membrane potential (Δψ)
• Consumes energy from the proton gradient
• Accounts for ~25% of the energy of the PMF

🔴 CLINICAL: Bongkrekic Acid Poisoning

• From fermented coconut or corn products contaminated with Burkholderia gladioli pathovar cocovenenans
• Outbreaks in Southeast Asia, China
• Inhibits ANT → ATP depletion → multiorgan failure
• Very high mortality rate (40-100%)

12.6 Phosphate Carrier (PiC)

• Symporter: transports Pi (H₂PO₄⁻) with H⁺ into the matrix
• Driven by the ΔpH component of the PMF
• Total cost of ATP synthesis and transport:
  • 3-4 H⁺ through ATP synthase
  • 1 H⁺ for phosphate import
  • Electrical potential used by ANT

12.7 Inhibitors of ATP Synthase (Complex V)

🔴 CLINICAL: Oligomycin Effect

• When oligomycin blocks ATP synthase → protons accumulate in IMS → PMF increases → proton pumping by Complexes I, III, IV stops → electron transport stops → O₂ consumption stops
• This is called "respiratory control" — the tight coupling between electron transport and ATP synthesis
• Shows that under normal conditions, ETC activity is directly coupled to ATP synthesis

🔴 CLINICAL: ATP Synthase Deficiency

• Mutations in MT-ATP6 (subunit a):
  • NARP syndrome (Neuropathy, Ataxia, Retinitis Pigmentosa): when mutant mtDNA load is 70-90%
  • Maternally Inherited Leigh Syndrome (MILS): when mutant load >90%
  • Most common mutation: m.8993T>G or m.8993T>C (both in MT-ATP6)
• MT-ATP8 mutations: rare; cardiomyopathy
• Nuclear-encoded assembly factors: TMEM70 mutations — most common cause of nuclear-encoded ATP synthase deficiency; 3-methylglutaconic aciduria, cardiomyopathy, lactic acidosis

---

13. THE PROTON MOTIVE FORCE (PMF)

13.1 Definition

• Δψ = membrane potential (voltage gradient) — inside (matrix) is negative; ~150-180 mV in mammals
• ΔpH = pH gradient — matrix is more alkaline (~0.5-1.0 pH units)
• Under physiological conditions: ~80% from Δψ, ~20% from ΔpH

13.2 Total Protons Pumped per NADH

---

14. CHEMIOSMOTIC HYPOTHESIS

Peter Mitchell (1961) — Nobel Prize in Chemistry (1978)

14.1 Key Postulates:

1. The ETC complexes are vectorially arranged in the IMM, pumping protons from matrix → IMS
2. The IMM is impermeable to protons (and most ions) — the proton gradient is maintained
3. The electrochemical proton gradient (PMF) stores energy
4. Protons flow back into the matrix only through ATP synthase → this drives ATP synthesis
5. The processes of electron transport and ATP synthesis are coupled through the PMF (not by chemical intermediates)

14.2 Evidence Supporting the Hypothesis:

1. Intact IMM is required for oxidative phosphorylation (disrupted membranes → no ATP synthesis)
2. Uncouplers (which dissipate the proton gradient) abolish ATP synthesis without stopping electron transport
3. Artificially created pH gradients across vesicles can drive ATP synthesis
4. ATP synthase reconstituted in artificial liposomes produces ATP when a pH gradient is applied
5. Ionophores that collapse the gradient inhibit ATP synthesis

---

15. P/O RATIOS AND ATP YIELD

15.1 Definition

15.2 Revised Values (Current Consensus)

• ~4 H⁺ needed per ATP (including transport costs)
• 10 H⁺ pumped per NADH; 6 H⁺ pumped per FADH₂

15.3 Total ATP Yield from Complete Oxidation of Glucose

• 10 NADH × 2.5 = 25 ATP
• 2 FADH₂ × 1.5 = 3 ATP
• 4 ATP/GTP (substrate level)
• But: glycolytic NADH (2) is in the cytoplasm and must be shuttled into mitochondria

• Malate-Aspartate Shuttle: delivers electrons as NADH → 2.5 ATP each → 5 ATP
• Glycerol-3-Phosphate Shuttle: delivers electrons as FADH₂ → 1.5 ATP each → 3 ATP

---

16. SHUTTLE SYSTEMS

16.1 Malate-Aspartate Shuttle

1. Cytoplasmic oxaloacetate + NADH → malate + NAD⁺ (cytoplasmic malate dehydrogenase)
2. Malate crosses IMM via the malate-α-ketoglutarate antiporter
3. Matrix malate → oxaloacetate + NADH (mitochondrial malate dehydrogenase)
4. Matrix oxaloacetate cannot cross IMM → transaminated to aspartate (by aspartate aminotransferase, using glutamate → α-ketoglutarate)
5. Aspartate exits via the glutamate-aspartate antiporter (electrogenic — driven by Δψ)
6. Cytoplasmic aspartate → oxaloacetate (by cytoplasmic aspartate aminotransferase)
7. α-ketoglutarate returns to matrix via the malate-αKG antiporter

16.2 Glycerol-3-Phosphate Shuttle

1. Cytoplasmic DHAP + NADH → glycerol-3-phosphate + NAD⁺ (cytoplasmic glycerol-3-phosphate dehydrogenase — NAD⁺-linked)
2. Glycerol-3-phosphate → DHAP + FADH₂ (mitochondrial glycerol-3-phosphate dehydrogenase — FAD-linked, located on outer surface of IMM, has active site facing IMS)
3. FADH₂ directly reduces CoQ in the IMM

🔴 CLINICAL: Malate-Aspartate Shuttle and Aralar1/AGC1 Deficiency

• SLC25A12 mutations (encoding mitochondrial aspartate-glutamate carrier isoform 1 — AGC1/Aralar1)
• Causes global cerebral hypomyelination, developmental delay, seizures
• Impaired transfer of reducing equivalents into brain mitochondria

---

17. INHIBITORS OF THE ETC — COMPREHENSIVE SUMMARY

17.1 Classification by Site

17.2 Effects of ETC Inhibitors

1. Upstream of the block: carriers become more reduced (can't pass electrons forward)
2. Downstream of the block: carriers become more oxidized (no electrons coming in)
3. O₂ consumption decreases (except with uncouplers)
4. ATP synthesis decreases
5. NADH/NAD⁺ ratio increases → inhibits TCA cycle and other NAD⁺-dependent reactions
6. Lactate production increases → lactic acidosis

---

18. UNCOUPLERS OF OXIDATIVE PHOSPHORYLATION

18.1 Definition

18.2 Mechanism

1. Pick up H⁺ on the IMS side (protonated form is lipid-soluble)
2. Cross the IMM in their protonated form
3. Release H⁺ on the matrix side
4. Return across the membrane in their anionic form
5. This short-circuits the proton gradient → collapses Δp

18.3 Effects of Uncoupling

18.4 Examples of Uncouplers

🔴 CLINICAL: 2,4-Dinitrophenol (DNP) Toxicity

• Used in the 1930s as a weight-loss agent due to uncoupling → increased metabolic rate → fat burning
• Banned by FDA in 1938 due to severe side effects
• Still available illegally online → causes deaths in body-builders/dieters
• Symptoms: profuse sweating, tachycardia, tachypnea, hyperthermia (potentially fatal malignant hyperthermia-like syndrome)
• Cataracts (with chronic use)
• No specific antidote — treatment is supportive: cooling, dantrolene may help
• Narrow therapeutic index → small dose increase can be lethal

🔴 CLINICAL: Aspirin (Salicylate) Overdose

• High-dose salicylates are:
  1. Uncouplers of oxidative phosphorylation (weak acid, lipid-soluble)
  2. Direct stimulants of the respiratory center (medullary)
• Clinical toxicity:
  • Respiratory alkalosis (early — direct stimulation of respiratory center)
  • Followed by metabolic acidosis (high anion gap — from uncoupling → lactate, ketoacids + salicylate itself)
  • Mixed respiratory alkalosis and metabolic acidosis is characteristic
  • Hyperthermia, tinnitus, diaphoresis, nausea/vomiting
  • Severe: pulmonary edema, cerebral edema, seizures, death
• Treatment: sodium bicarbonate (alkalinize urine and blood → traps salicylate in ionized form in urine), hemodialysis for severe cases, cooling

18.5 Thermogenin (UCP1) and Brown Adipose Tissue (BAT)

🔴 CLINICAL: Non-Shivering Thermogenesis

• Brown adipose tissue (BAT) contains abundant mitochondria (brown color from cytochromes)
• Contains UCP1 (Uncoupling Protein 1 / Thermogenin) — a natural proton channel in the IMM
• UCP1 allows H⁺ to re-enter the matrix without passing through ATP synthase → energy released as HEAT
• Important in:
  • Neonates (who cannot shiver) — major source of heat production
  • Hibernating animals
  • Adults (recently discovered to have metabolically active BAT, especially in supraclavicular, paravertebral, perirenal regions)
• Regulation of UCP1:
  • Activated by: free fatty acids, norepinephrine (via β₃-adrenergic receptors → cAMP → PKA → hormone-sensitive lipase → FFA release → FFA activates UCP1)
  • Inhibited by: purine nucleotides (GDP, GTP, ADP, ATP) — bind and block the channel
• Cold exposure → sympathetic nervous system → norepinephrine → β₃ receptors on BAT → thermogenesis
• Thyroid hormones (T₃) upregulate UCP1 expression → explains heat intolerance in hyperthyroidism
• BAT and obesity: less active BAT is associated with obesity; activating BAT is a potential anti-obesity strategy

18.6 Other Uncoupling Proteins

🔴 CLINICAL: UCP2 and Type 2 Diabetes

• UCP2 in pancreatic β-cells may reduce ATP production → decreased ATP/ADP ratio → impaired glucose-stimulated insulin secretion
• UCP2 polymorphisms have been associated with type 2 diabetes risk and obesity (though controversial)
• UCP2 knockout mice show improved insulin secretion

---

19. TIGHT COUPLING, RESPIRATORY CONTROL, AND REGULATION

19.1 Respiratory Control

• Under normal conditions, electron transport is tightly coupled to ATP synthesis
• The rate of O₂ consumption (electron transport) is determined by the availability of ADP
• When ADP levels are low (cell has enough ATP) → no ATP synthesis needed → proton gradient builds up → back-pressure inhibits ETC → O₂ consumption decreases
• When ADP levels are high (ATP is being used) → ADP enters mitochondria → ATP synthase becomes active → proton gradient is consumed → ETC speeds up → O₂ consumption increases

19.2 Respiratory States (Chance & Williams)

• Respiratory Control Ratio (RCR) = State 3 rate / State 4 rate
• Normal RCR = 5-10 (indicates tight coupling)
• Low RCR suggests uncoupling or damaged mitochondria

19.3 Regulation of ETC

---

20. REACTIVE OXYGEN SPECIES (ROS)

20.1 Overview

20.2 Sites of ROS Production

20.3 Types of ROS

20.4 Antioxidant Defense Systems

20.5 ROS-Mediated Damage

🔴 CLINICAL: ROS and Disease

• Aging: "Mitochondrial free radical theory of aging" — cumulative mtDNA damage → declining ETC function → more ROS → more damage (vicious cycle)
• Ischemia-Reperfusion Injury: during reperfusion, sudden O₂ reintroduction → massive ROS burst from dysfunctional ETC → cell death (relevant in MI, stroke, organ transplantation)
• Neurodegenerative diseases: Parkinson's (Complex I deficiency, ROS in substantia nigra), Alzheimer's, ALS (SOD1 mutations in familial ALS)
• Cancer: ROS cause DNA mutations → oncogenic transformation; paradoxically, many cancer cells have increased ROS which promotes proliferation and genomic instability
• Diabetes: Hyperglycemia → increased ETC substrate → ROS overproduction → diabetic complications (retinopathy, nephropathy, neuropathy)

🔴 CLINICAL: Superoxide Dismutase and ALS

• ~20% of familial ALS (amyotrophic lateral sclerosis) cases involve mutations in SOD1 (Cu/ZnSOD)
• Not a loss-of-function → gain of toxic function (misfolded SOD1 aggregates → motor neuron death)
• Autosomal dominant

🔴 CLINICAL: Friedreich's Ataxia and Iron-Sulfur Clusters

• Autosomal recessive; most common hereditary ataxia
• GAA trinucleotide repeat expansion in FXN gene (frataxin)
• Frataxin: mitochondrial protein involved in iron-sulfur cluster assembly and iron homeostasis
• Frataxin deficiency → impaired Fe-S cluster synthesis → dysfunctional Complexes I, II, III and aconitase
• Mitochondrial iron accumulation → Fenton reaction → ROS damage
• Clinical: progressive gait and limb ataxia (cerebellar and spinocerebellar), dysarthria, hypertrophic cardiomyopathy (major cause of death), diabetes mellitus, absent deep tendon reflexes (peripheral neuropathy), pes cavus, scoliosis, upgoing plantars (corticospinal tract involvement)
• Treatment: idebenone (CoQ analog, antioxidant — limited benefit), omaveloxolone (Nrf2 activator — FDA approved 2023)

---

21. SUPERCOMPLEXES (RESPIRASOMES)

21.1 Concept

21.2 Functional Significance

• Substrate channeling: CoQ and cytochrome c may be channeled between complexes → faster electron transfer → reduced ROS production
• Enhanced efficiency: reduces the distance electrons must travel
• Reduced ROS: shorter transit time → less chance of electron leak to O₂
• Stabilization: individual complexes are stabilized by supercomplex formation (Complex I is unstable without Complex III)
• Cardiolipin is essential for supercomplex assembly

🔴 CLINICAL: Supercomplex Dysfunction

• Heart failure: decreased supercomplex assembly → increased ROS, decreased ATP production
• Barth syndrome: cardiolipin deficiency → impaired supercomplex formation
• Aging: decreased supercomplex levels in aged tissues

---

22. COMPREHENSIVE CLINICAL CORRELATIONS

22.1 Mitochondrial Diseases — Overview

• Brain: encephalopathy, seizures, stroke-like episodes, cognitive decline, ataxia
• Muscle: myopathy, exercise intolerance, ophthalmoplegia
• Heart: cardiomyopathy, conduction defects
• Eye: optic neuropathy, retinitis pigmentosa, ptosis
• Ear: sensorineural hearing loss
• Endocrine: diabetes mellitus, growth hormone deficiency
• GI: pseudo-obstruction
• Kidney: tubular dysfunction, Fanconi syndrome
• Liver: hepatopathy

• Elevated serum lactate (most consistent finding)
• Elevated lactate:pyruvate ratio (>20:1, indicating NADH/NAD⁺ imbalance)
• Elevated alanine (transamination of pyruvate)
• Ragged red fibers (RRF) on Gomori trichrome stain of muscle biopsy (subsarcolemmal accumulation of abnormal mitochondria)
• COX-negative fibers (cytochrome c oxidase staining absent in affected fibers)
• Strongly SDH-reactive fibers ("ragged blue fibers")
• MRI: stroke-like lesions not conforming to vascular territories, bilateral basal ganglia lesions (Leigh syndrome), cerebellar atrophy
• Genetic testing: mtDNA sequencing, nuclear gene panels, whole exome/genome sequencing
• Enzyme analysis: measurement of individual complex activities in muscle tissue

22.2 Specific Mitochondrial Syndromes

MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like episodes)

• Mutation: m.3243A>G in MT-TL1 (tRNA^Leu(UUR)) — ~80% of cases
• Also affects Complex I function predominantly
• Onset: usually childhood-young adulthood (onset before age 40)
• Features:
  • Stroke-like episodes (NOT true strokes — do not follow vascular territories; often occipital/parietal)
  • Lactic acidosis
  • Seizures (often associated with stroke-like episodes)
  • Myopathy, exercise intolerance
  • Sensorineural hearing loss
  • Diabetes mellitus (m.3243A>G is a common cause of maternally inherited diabetes and deafness — MIDD)
  • Short stature
  • Migraine headaches
  • Cognitive decline
  • Ragged red fibers on muscle biopsy
• Important: the same m.3243A>G mutation can cause MELAS, MIDD, or progressive external ophthalmoplegia (PEO) — variable phenotype due to heteroplasmy

MERRF (Myoclonic Epilepsy with Ragged Red Fibers)

• Mutation: m.8344A>G in MT-TK (tRNA^Lys) — ~80% of cases
• Features:
  • Myoclonus (stimulus-sensitive, progressive)
  • Generalized epilepsy
  • Myopathy with ragged red fibers
  • Cerebellar ataxia
  • Lipomas (multiple, symmetric — especially cervical)
  • Sensorineural hearing loss
  • Short stature, optic atrophy, dementia
  • Lactic acidosis

Leigh Syndrome (Subacute Necrotizing Encephalomyelopathy)

• Most common mitochondrial disease in infancy/childhood
• Can be caused by mutations in >75 different genes (both mtDNA and nuclear)
  • Complex I (most common), Complex II, Complex III, Complex IV, Complex V, PDH, CoQ₁₀ biosynthesis
  • Common mtDNA mutations: MT-ATP6 (m.8993T>G/C), MT-ND genes
  • Common nuclear gene mutations: SURF1 (Complex IV assembly), NDUFS4 (Complex I), SDHA
• Pathology: bilateral, symmetric necrotizing lesions in basal ganglia (putamen, caudate), brainstem, thalamus, spinal cord
• Features:
  • Developmental regression
  • Hypotonia → spasticity
  • Respiratory abnormalities (central hypoventilation — brainstem involvement)
  • Eye movement abnormalities (nystagmus, ophthalmoplegia)
  • Dysphagia
  • Lactic acidosis
  • Usually fatal in early childhood (but variable)
• MRI: bilateral symmetric T2-hyperintense lesions in basal ganglia and brainstem

🔴 CLINICAL: SURF1 Mutations and Leigh Syndrome

• SURF1 is a Complex IV assembly factor (involved in heme a insertion)
• Autosomal recessive
• Most common nuclear gene cause of COX-deficient Leigh syndrome
• Muscle biopsy: COX-negative fibers with SDH-positive fibers

Kearns-Sayre Syndrome (KSS)

• Caused by large-scale mtDNA deletions (typically 1.3-10 kb; most common: "common deletion" — 4,977 bp deletion removing genes from ATPase8 to ND5)
• Usually sporadic (not maternally inherited — deletions arise de novo in oocyte or early embryogenesis)
• Diagnostic triad (all required):
  1. Progressive External Ophthalmoplegia (PEO) — ptosis + restricted eye movements
  2. Pigmentary retinopathy ("salt and pepper" fundus)
  3. Onset before age 20
• Plus at least one of: cardiac conduction defect, cerebellar ataxia, CSF protein >100 mg/dL
• Other features: short stature, hearing loss, endocrinopathies (diabetes, hypoparathyroidism, growth hormone deficiency), cognitive decline
• Cardiac conduction defects are life-threatening → may require pacemaker (heart block can cause sudden death)
• Ragged red fibers and COX-negative fibers on muscle biopsy

Pearson Syndrome

• Also caused by large-scale mtDNA deletions (same deletions as KSS)
• Presents in infancy (much earlier than KSS)
• Sideroblastic anemia + pancreatic exocrine insufficiency
• Bone marrow: vacuolization of precursors, ringed sideroblasts
• Many die in infancy; survivors may develop KSS in later years
• Same deletion → different phenotype due to tissue distribution of mutant mtDNA

Chronic Progressive External Ophthalmoplegia (CPEO)

• PEO without the full features of KSS
• Can be caused by:
  • Single mtDNA deletions (sporadic)
  • Nuclear gene mutations affecting mtDNA maintenance → multiple mtDNA deletions:
    • POLG (mitochondrial DNA polymerase γ)
    • Twinkle/TWNK (mitochondrial helicase)
    • ANT1/SLC25A4 (adenine nucleotide translocator)
    • RRM2B (ribonucleotide reductase)
• Features: progressive ptosis, ophthalmoplegia, exercise intolerance

🔴 CLINICAL: POLG Mutations

• POLG encodes the catalytic subunit of mitochondrial DNA polymerase γ (responsible for mtDNA replication)
• Autosomal recessive (or dominant)
• Can cause a wide spectrum:
  • Alpers-Huttenlocher syndrome: childhood; progressive encephalopathy, intractable seizures, hepatopathy → liver failure (especially with valproate — VALPROATE IS CONTRAINDICATED in POLG mutations as it precipitates fatal hepatotoxicity)
  • CPEO (with multiple mtDNA deletions)
  • Ataxia-neuropathy spectrum (MIRAS — Mitochondrial Recessive Ataxia Syndrome, SANDO — Sensory Ataxic Neuropathy, Dysarthria, Ophthalmoparesis)
  • Myocerebrohepatopathy spectrum

NARP (Neuropathy, Ataxia, Retinitis Pigmentosa)

• Mutation: m.8993T>G (or T>C) in MT-ATP6
• When heteroplasmy level is 70-90% → NARP
• When >90% → Leigh syndrome (maternally inherited Leigh syndrome — MILS)
• Features: peripheral neuropathy (sensorimotor), cerebellar ataxia, retinitis pigmentosa, proximal weakness, developmental delay

Aminoglycoside-Induced Ototoxicity

• Mutation: m.1555A>G in MT-RNR1 (12S rRNA)
• This mutation makes the mitochondrial ribosome more "bacterial-like" → aminoglycosides (which target bacterial ribosomes) also damage mitochondrial translation
• Individuals with this mutation: even a single dose of aminoglycosides can cause permanent bilateral sensorineural hearing loss
• Important genetic counseling point; some hospitals screen for this mutation before aminoglycoside use

22.3 Acquired Conditions Affecting the ETC

Ischemia-Reperfusion Injury

• During ischemia: O₂ deprived → ETC cannot function → NADH/FADH₂ accumulate → succinate accumulates (via reversal of Complex II) → ATP depleted → anaerobic glycolysis → acidosis → Ca²⁺ accumulation → cell damage
• During reperfusion: O₂ reintroduced → accumulated succinate is rapidly oxidized by Complex II → reverse electron transport (RET) through Complex I → massive superoxide production → oxidative damage, cell death, inflammation
• Clinical relevance: myocardial infarction reperfusion, stroke thrombolysis, organ transplantation
• Therapeutic targets: preventing succinate accumulation, inhibiting RET, antioxidants

Sepsis

• NO overproduction (iNOS) → Complex IV inhibition
• ROS-mediated ETC damage
• Mitochondrial dysfunction → bioenergetic failure → organ failure

Cancer (Warburg Effect)

• Many cancer cells rely on aerobic glycolysis ("Warburg effect") despite functional mitochondria
• Some cancers have ETC mutations:
  • SDH mutations (paraganglioma, pheochromocytoma — discussed above)
  • Fumarate hydratase (FH) mutations → hereditary leiomyomatosis and renal cell cancer (HLRCC)
  • Isocitrate dehydrogenase (IDH) mutations → gliomas, AML (oncometabolite 2-hydroxyglutarate)

Drug-Induced Mitochondrial Toxicity

22.4 Malignant Hyperthermia

🔴 CLINICAL: Malignant Hyperthermia

• Not a primary ETC disorder but involves catastrophic thermogenesis
• Autosomal dominant; mutations in RYR1 (Ryanodine Receptor 1) — ~70% of cases — or CACNA1S (dihydropyridine receptor)
• Triggered by volatile anesthetics (halothane, sevoflurane, desflurane, isoflurane) and/or succinylcholine
• Mechanism: uncontrolled Ca²⁺ release from sarcoplasmic reticulum → sustained muscle contraction → massively increased ATP consumption → accelerated ETC activity → excessive heat production, CO₂ production
• Features: rapidly rising temperature, muscle rigidity (especially masseter/jaw rigidity), tachycardia, hypercarbia, metabolic acidosis, rhabdomyolysis, hyperkalemia
• Treatment: dantrolene (blocks RyR1 Ca²⁺ release), active cooling, treat hyperkalemia and acidosis
• Not the same mechanism as DNP uncoupling but shares the feature of excessive heat production

22.5 Thyroid Hormones and ETC

• Hyperthyroidism: increased expression of ETC components + increased UCP expression → increased O₂ consumption, heat production → heat intolerance, weight loss, sweating, tachycardia, increased BMR
• Hypothyroidism: decreased ETC activity → cold intolerance, weight gain, fatigue, decreased BMR

---

23. SUMMARY TABLES

Table 1: Complete Summary of ETC Complexes

Table 2: Proton Accounting

Table 3: ATP Yield

Table 4: Vitamins and Minerals in ETC

Table 5: Inhibitors vs. Uncouplers

---

FINAL INTEGRATIVE SUMMARY

• Inhibition (at any complex — leading to electron transport cessation, ATP depletion, and lactic acidosis)
• Uncoupling (dissipation of the proton gradient — electron transport continues but ATP is not made; energy is released as heat)
• Genetic disorders (mutations in either mtDNA or nuclear genes encoding ETC subunits, assembly factors, or mtDNA maintenance proteins — producing a vast spectrum of multisystem diseases preferentially affecting high-energy tissues)

• Normal energy metabolism
• The pathophysiology of mitochondrial diseases
• Mechanisms of toxicity (cyanide, CO, drug-induced mitochondrial toxicity)
• The basis of thermogenesis
• The role of ROS in aging, neurodegeneration, and ischemia-reperfusion injury
• Emerging therapeutic targets in cancer, obesity, and metabolic disease

---

1. Section 1 — Introduction/Overview
   • Full ETC schematic showing all 5 complexes in the inner mitochondrial membrane, electron flow from NADH/FADH₂ to O₂, and proton pumping
2. Section 2 — Mitochondrial Anatomy
   • Diagram of the inner mitochondrial membrane and the five subunits of the ETC embedded within it, alongside cristae structure
3. Section 4 — Thermodynamic Basis
   • Free energy diagram showing the energetically downhill flow of electrons — large drops at Complexes I, III, and IV (the three proton-pumping sites)
4. Section 6 — Complex I
   • L-shaped Complex I schematic with hydrophilic peripheral arm (FMN + Fe-S clusters) projecting into the matrix and hydrophobic membrane arm containing ND2/ND4/ND5 antiporter-like subunits
5. Section 9 — Complex III / Q Cycle
   • Two images here: the Complex III/cytochrome bc₁ structure showing the Qo and Qi sites, and the modified Q cycle schematic showing how semiquinone accumulation at the Qp site generates superoxide (directly relevant to ROS pathophysiology and Antimycin A toxicity)
6. Section 12 — ATP Synthase
   • Two images: the F₁F₀ structure showing the c-ring rotor, central γ stalk, peripheral stator, and α₃β₃ hexamer; plus the E. coli ATP synthase annotated structural diagram for clarity
7. Section 13 — Proton Motive Force
   • Integrated ETC + ATP synthase overview showing the complete proton accounting (10 H⁺ per NADH, 6 H⁺ per FADH₂) and the chemiosmotic coupling
8. Section 21 — Supercomplexes / Final Summary
   • Respirasome schematic showing Complexes I, III₂, IV₁ with cofactor positions (FMN in blue, Fe-S in purple, quinols in green, hemes in red, copper in orange)

THE ELECTRON TRANSPORT CHAIN (ETC) — A COMPREHENSIVE TREATISE

---

TABLE OF CONTENTS

1. Introduction & Overview
2. Location and Structural Organization
3. Historical Background
4. Thermodynamic Basis
5. Components of the ETC
6. Complex I (NADH: Ubiquinone Oxidoreductase)
7. Complex II (Succinate: Ubiquinone Oxidoreductase)
8. Ubiquinone (Coenzyme Q)
9. Complex III (Ubiquinol: Cytochrome c Oxidoreductase)
10. Cytochrome c
11. Complex IV (Cytochrome c Oxidase)
12. Complex V (ATP Synthase) — Oxidative Phosphorylation
13. The Proton Motive Force
14. Chemiosmotic Hypothesis
15. P/O Ratios and ATP Yield
16. Shuttle Systems
17. Inhibitors of ETC
18. Uncouplers of ETC
19. Regulation of ETC
20. Reactive Oxygen Species (ROS)
21. Supercomplex Organization (Respirasomes)
22. Clinical Correlations (Comprehensive)
23. Summary Tables

---

1. INTRODUCTION & OVERVIEW

Key Concepts:

• Oxidation = loss of electrons
• Reduction = gain of electrons
• Electrons flow from carriers with more negative (lower) reduction potential to carriers with more positive (higher) reduction potential
• The overall reactions:

NADH + H⁺ + ½O₂ → NAD⁺ + H₂O (ΔG°' = −220 kJ/mol = −52.6 kcal/mol)

FADH₂ + ½O₂ → FAD + H₂O (ΔG°' = −152 kJ/mol = −36.4 kcal/mol)

---

2. LOCATION AND STRUCTURAL ORGANIZATION

2.1 Mitochondrial Anatomy

2.2 Cardiolipin

• Diphosphatidylglycerol — a unique phospholipid found almost exclusively in the IMM
• Contains 4 fatty acid chains (usually linoleic acid)
• Essential for the function of Complex III, Complex IV, and ATP synthase
• Provides structural support and maintains the impermeability of the IMM to protons

🔴 CLINICAL: Barth Syndrome

• X-linked recessive disorder
• Mutation in the tafazzin gene (TAZ) on Xq28
• Tafazzin is a transacylase required for cardiolipin remodeling
• Results in abnormal cardiolipin → impaired ETC function
• Features: dilated cardiomyopathy, skeletal myopathy, neutropenia, 3-methylglutaconic aciduria, growth retardation
• Predominantly affects males

2.3 Mitochondrial DNA (mtDNA)

• Circular, double-stranded DNA — 16,569 base pairs
• Encodes 37 genes: 13 polypeptides (all ETC/ATP synthase subunits), 22 tRNAs, 2 rRNAs
• Maternal inheritance (mitochondria come from the ovum)
• No histones, limited repair mechanisms → high mutation rate (~10x nuclear DNA)
• Heteroplasmy: a cell can contain a mixture of normal and mutant mtDNA
• Threshold effect: disease manifests when the proportion of mutant mtDNA exceeds a critical threshold

🔴 CLINICAL: Mitochondrial Inheritance Patterns

• All children of an affected mother may be affected (but variable expressivity due to heteroplasmy)
• An affected father CANNOT transmit the disease
• Tissues with high energy demands (brain, heart, skeletal muscle, retina, kidney) are most affected

---

3. HISTORICAL BACKGROUND

---

4. THERMODYNAMIC BASIS

4.1 Standard Reduction Potential (E°')

4.2 Free Energy Relationship

• n = number of electrons transferred
• F = Faraday constant (96,485 J/V·mol = 23.06 kcal/V·mol)
• ΔE°' = E°'(acceptor) − E°'(donor)

4.3 Sites of Sufficient Free Energy for ATP Synthesis

1. Complex I: NADH → CoQ (ΔE = 0.36 V → ΔG = −69.5 kJ/mol)
2. Complex III: CoQH₂ → Cytochrome c (ΔE = 0.21 V → ΔG = −40.5 kJ/mol)
3. Complex IV: Cytochrome c → O₂ (ΔE = 0.57 V → ΔG = −110 kJ/mol)

---

5. COMPONENTS OF THE ETC — ELECTRON CARRIERS

5.1 Types of Electron Carriers

5.2 Flavin Nucleotides (FMN and FAD)

• Derived from Riboflavin (Vitamin B₂)
• Can accept 1 or 2 electrons (can form a semiquinone radical intermediate)
• FMN is the first electron acceptor in Complex I
• FAD is the prosthetic group in Complex II (succinate dehydrogenase)

5.3 Iron-Sulfur Clusters

• Also called non-heme iron proteins
• Contain iron atoms coordinated with inorganic sulfide (S²⁻) and/or cysteine sulfur from the protein
• Types:
  • [2Fe-2S] — Rieske center in Complex III (unique: one Fe coordinated by 2 histidines instead of cysteines)
  • [4Fe-4S] — most common, found in Complexes I, II, III
  • [3Fe-4S] — found in Complex II
• Transfer only 1 electron at a time despite having multiple iron atoms
• Complex I contains 8 Fe-S clusters forming an electron "wire" ~95 Å long

5.4 Heme Groups and Cytochromes

5.5 Copper Centers

• CuA in Complex IV: dinuclear copper center; first electron acceptor from cytochrome c
• CuB in Complex IV: paired with heme a₃ in the binuclear center; directly involved in O₂ binding and reduction

---

6. COMPLEX I — NADH:UBIQUINONE OXIDOREDUCTASE (EC 1.6.5.3)

6.1 Structure

• Largest respiratory complex
• ~1,000 kDa (1 MDa) in mammals
• 45 subunits in mammals (7 encoded by mtDNA: ND1–ND6, ND4L; 38 nuclear-encoded)
• Shaped like an "L" or a boot:
  • Hydrophilic arm (peripheral arm): projects into the matrix; contains FMN and all Fe-S clusters
  • Hydrophobic arm (membrane arm): embedded in the IMM; contains the proton-pumping machinery
• Contains:
  • 1 FMN (flavin mononucleotide)
  • 8 iron-sulfur clusters (N1a, N1b, N2, N3, N4, N5, N6a, N6b)
  • The Fe-S clusters form a ~95 Å electron transfer wire

6.2 Mechanism

1. NADH binds to the hydrophilic arm and donates 2 electrons as a hydride ion (H⁻) to FMN → FMNH₂
2. FMNH₂ passes electrons one at a time through the chain of 8 Fe-S clusters
3. The terminal Fe-S cluster N2 (highest potential in the chain) donates electrons to ubiquinone (CoQ)
4. CoQ is reduced: Q → QH• (semiquinone) → QH₂ (ubiquinol)
5. The energy released drives conformational changes in the membrane arm that translocate 4 H⁺ from the matrix to the IMS

6.3 Proton Pumping Mechanism

• The membrane arm contains three antiporter-like subunits (ND2, ND4, ND5) each pumping 1 H⁺
• A fourth proton is pumped at the junction near the ubiquinone-binding site (ND1/ND6 region)
• Total: 4 H⁺ pumped per NADH (per 2 electrons)
• Mechanism: long-range conformational coupling — a "piston-like" mechanism transmitted through a long amphipathic helix

6.4 Overall Reaction

NADH + H⁺ + Q + 4H⁺(matrix) → NAD⁺ + QH₂ + 4H⁺(IMS)

6.5 Inhibitors of Complex I

🔴 CLINICAL: Rotenone and Parkinson's Disease

• Chronic rotenone exposure in animal models produces Parkinsonism including selective dopaminergic neuron death and Lewy body-like inclusions
• Dopaminergic neurons in the substantia nigra pars compacta are especially vulnerable due to high energy demands and high oxidative stress
• Epidemiological studies link pesticide exposure (rotenone, paraquat) to increased Parkinson's disease risk

🔴 CLINICAL: MPTP Toxicity (Drug-induced Parkinsonism)

• MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) — contaminant of synthetic heroin ("designer drug")
• MPTP crosses the blood-brain barrier → taken up by astrocytes → converted to MPP⁺ by MAO-B
• MPP⁺ is selectively taken up by dopaminergic neurons via the dopamine transporter (DAT)
• MPP⁺ inhibits Complex I → ATP depletion, ROS generation → selective death of dopaminergic neurons
• Produces acute, irreversible Parkinsonism
• Prevention: MAO-B inhibitors (selegiline/rasagiline) block MPTP → MPP⁺ conversion

🔴 CLINICAL: Leber's Hereditary Optic Neuropathy (LHON)

• Mitochondrial inheritance (maternal)
• Point mutations in mtDNA genes encoding Complex I subunits
• Most common mutations: m.11778G>A (ND4, ~70% of cases), m.3460G>A (ND1), m.14484T>C (ND6)
• Presents in young adults (15-35 years), more commonly in males (male:female = 4:1)
• Acute or subacute painless bilateral central vision loss (sequential, one eye then the other within weeks to months)
• Loss of central vision with centrocecal scotoma (central blind spot)
• Optic disc pseudoedema, peripapillary telangiectatic microangiopathy (does NOT leak on fluorescein angiography)
• Eventually → optic atrophy
• No consistently effective treatment; idebenone (CoQ analog) may have some benefit
• Smoking and alcohol use may trigger/worsen the disease

🔴 CLINICAL: Complex I Deficiency

• Most common cause of mitochondrial disease in children
• Clinical spectrum: Leigh syndrome, MELAS-like syndrome, neonatal lactic acidosis, hypertrophic cardiomyopathy, leukodystrophy
• Lab findings: elevated lactate, elevated lactate:pyruvate ratio (>20:1), elevated alanine

---

7. COMPLEX II — SUCCINATE:UBIQUINONE OXIDOREDUCTASE (EC 1.3.5.1)

7.1 Structure

• Smallest respiratory complex: ~124 kDa
• 4 subunits — ALL nuclear-encoded (the ONLY ETC complex entirely nuclear-encoded)
  • SDHA: flavoprotein subunit; contains covalently bound FAD and the succinate-binding site
  • SDHB: iron-sulfur protein; contains three Fe-S clusters: [2Fe-2S], [4Fe-4S], [3Fe-4S]
  • SDHC and SDHD: membrane-anchor subunits; contain heme b and the ubiquinone-binding site
• Part of both the TCA cycle (as succinate dehydrogenase, enzyme #6) and the ETC

7.2 Mechanism

1. Succinate is oxidized to fumarate at the SDHA subunit
2. FAD is reduced to FADH₂ (covalently bound — does NOT dissociate)
3. Electrons pass through the three Fe-S clusters in SDHB: [2Fe-2S] → [4Fe-4S] → [3Fe-4S]
4. Electrons are donated to ubiquinone (CoQ) at the Q-binding site → ubiquinol (QH₂)

7.3 Key Points

• Does NOT pump protons — insufficient free energy change (ΔG ≈ −6 kJ/mol for FAD → CoQ transfer)
• FADH₂ generated here enters the chain at the level of CoQ, bypassing Complex I
• Therefore, FADH₂ from Complex II generates fewer ATP than NADH (1.5 vs. 2.5 ATP)

7.4 Overall Reaction

Succinate + Q → Fumarate + QH₂ (No proton pumping)

7.5 Inhibitors of Complex II

🔴 CLINICAL: Hereditary Paraganglioma-Pheochromocytoma Syndrome

• Germline mutations in SDHB, SDHC, SDHD (and also SDHA, SDHAF2)
• These are tumor suppressor genes (loss-of-function mutations)
• SDH deficiency → accumulation of succinate → inhibits prolyl hydroxylases (PHDs) → stabilization of HIF-1α → pseudohypoxic signaling → angiogenesis, proliferation (oncometabolite mechanism)
• Clinical manifestations: Paragangliomas, Pheochromocytomas, GISTs, Renal cell carcinoma
• SDHB mutations: highest malignancy risk (~30-40% metastatic)
• SDHD mutations: predominantly paternally inherited expression (genomic imprinting)
• Screening: plasma/urine metanephrines and catecholamines
• IHC: loss of SDHB staining in tumor tissue is a marker

🔴 CLINICAL: 3-Nitropropionic Acid (3-NPA) Toxicity

• Found in moldy sugarcane (Arthrinium saccharicola fungus)
• Irreversibly inhibits Complex II (SDH)
• Causes acute encephalopathy with selective bilateral striatal (basal ganglia) necrosis
• Mimics Huntington's disease pathology; used as an experimental model for HD

7.6 Other FADH₂-Linked Dehydrogenases

🔴 CLINICAL: Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) / Glutaric Aciduria Type II

• Deficiency of ETF or ETF:ubiquinone oxidoreductase (ETF-QO)
• Biochemical: elevated multiple acylcarnitines, organic acids (glutaric, ethylmalonic, adipic, suberic acids)
• Clinical: severe neonatal form or milder late-onset form (lipid storage myopathy)
• Treatment: riboflavin (B₂) — many cases are riboflavin-responsive

---

8. UBIQUINONE (COENZYME Q / CoQ₁₀)

8.1 Structure

• 2,3-dimethoxy-5-methyl-1,4-benzoquinone with an isoprenoid side chain
• In humans: 10 isoprenoid units (CoQ₁₀ or ubiquinone-50)
• Long hydrophobic tail → freely dissolves in the lipid bilayer of the IMM
• Small, lipid-soluble, mobile electron carrier — NOT a protein

8.2 Redox States

1. Ubiquinone (Q) — fully oxidized
2. Semiquinone radical (QH• or Q•⁻) — partially reduced (one electron)
3. Ubiquinol (QH₂) — fully reduced (two electrons)

8.3 Function

• Collects electrons from Complexes I and II (and other FADH₂-linked dehydrogenases)
• Shuttles electrons to Complex III
• The CoQ pool contains ~10× more CoQ than Complex III → functions as a mobile electron buffer

8.4 Biosynthesis

• Synthesized endogenously via the mevalonate pathway (same pathway as cholesterol synthesis)
• The benzoquinone ring is derived from tyrosine (or phenylalanine)
• The isoprenoid tail is from the mevalonate pathway (farnesyl pyrophosphate → decaprenyl-PP)

🔴 CLINICAL: CoQ₁₀ Deficiency

• Primary CoQ₁₀ deficiency: autosomal recessive mutations in CoQ₁₀ biosynthetic pathway genes (COQ2, COQ4, COQ6, COQ7, COQ8A, COQ8B, COQ9, PDSS1, PDSS2)
• Clinical phenotypes: Cerebellar ataxia (most common), Steroid-resistant nephrotic syndrome (COQ2, COQ6, COQ8B), Encephalomyopathy, Isolated myopathy, Multisystem infantile form
• Secondary CoQ₁₀ deficiency: seen in mitochondrial diseases, aging, statin therapy
• Treatment: oral CoQ₁₀ supplementation (one of the few treatable mitochondrial disorders)

🔴 CLINICAL: Statins and CoQ₁₀

• Statins (HMG-CoA reductase inhibitors) inhibit the mevalonate pathway
• Reduces not only cholesterol but also CoQ₁₀ and dolichol synthesis
• May contribute to statin-associated myopathy/myalgia (biologically plausible; evidence mixed)

8.5 CoQ₁₀ as an Antioxidant

• Ubiquinol (QH₂) is a potent lipid-soluble antioxidant
• Protects membrane lipids from peroxidation
• Regenerates vitamin E (α-tocopherol) from its radical form

---

9. COMPLEX III — UBIQUINOL:CYTOCHROME c OXIDOREDUCTASE (EC 1.10.2.2)

9.1 Structure

• ~240 kDa as a functional homodimer (each monomer ~11 subunits in mammals)
• 11 subunits per monomer: 1 mtDNA-encoded (cytochrome b) + 10 nuclear-encoded
• Key catalytic subunits:
  1. Cytochrome b: contains two heme b groups — heme bL (low potential) and heme bH (high potential)
  2. Rieske iron-sulfur protein: contains [2Fe-2S] cluster — one Fe coordinated by 2 histidines (unique; gives higher reduction potential: +0.28 V)
  3. Cytochrome c₁: contains heme c₁

9.2 The Q Cycle (Mitchell's Q Cycle)

• Transfers electrons from a 2-electron carrier (QH₂) to a 1-electron carrier (cytochrome c)
• Pumps protons across the membrane
• Effectively doubles the number of protons translocated per QH₂

• Qp site (Qo site) — P-side (IMS side / positive side) — where QH₂ is oxidized
• Qn site (Qi site) — N-side (matrix side / negative side) — where Q is reduced

First Half of the Q Cycle:

1. QH₂ binds at the Qp site
2. First electron → Rieske [2Fe-2S] → Cytochrome c₁ → Cytochrome c (departs reduced)
3. 2 H⁺ released into the IMS
4. Second electron → low-potential pathway: QH• → heme bL → heme bH → reduces Q to Q•⁻ (semiquinone) at the Qn site

Second Half of the Q Cycle:

1. A second QH₂ binds at the Qp site
2. First electron → Rieske → cyt c₁ → second cytochrome c (reduced and departs)
3. 2 more H⁺ released into IMS
4. Second electron → heme bL → heme bH → reduces the semiquinone (Q•⁻) at Qn to QH₂ (picking up 2 H⁺ from the matrix)

Net Q Cycle (per pair of electrons reaching cytochrome c):

QH₂ + 2 cyt c (ox) + 2H⁺(matrix) → Q + 2 cyt c (red) + 4H⁺(IMS)

9.3 Inhibitors of Complex III

🔴 CLINICAL: Antimycin A and ROS

• When Antimycin A blocks the Qn site, the semiquinone radical (Q•⁻) at the Qp site accumulates
• This semiquinone can donate its electron directly to O₂ → forming superoxide (O₂•⁻)
• Complex III (Qp site) is a major site of mitochondrial ROS production

🔴 CLINICAL: Complex III Deficiency

• Rare; caused by mutations in:
  • Cytochrome b (mtDNA — MT-CYB)
  • BCS1L (assembly factor for Rieske protein)
• BCS1L mutations cause:
  • GRACILE syndrome (Growth Retardation, Aminoaciduria, Cholestasis, Iron overload, Lactic acidosis, Early death) — Finnish heritage
  • Björnstad syndrome (sensorineural deafness + pili torti — twisted hair)
• MT-CYB mutations: exercise intolerance, myopathy, cardiomyopathy

---

10. CYTOCHROME c

10.1 Structure and Function

• Small (~12.4 kDa), highly conserved, water-soluble protein
• Contains one heme c (covalently attached via thioether bonds to two cysteine residues — -CXXCH- motif)
• Located in the intermembrane space
• Peripheral membrane protein — loosely associated with the outer surface of the IMM via cardiolipin
• Transfers one electron from Complex III (cyt c₁) → Complex IV (CuA)

10.2 Role in Apoptosis

🔴 CLINICAL: Cytochrome c and Apoptosis (Intrinsic Pathway)

• During intrinsic (mitochondrial) apoptosis:
  1. Pro-apoptotic stimuli activate BH3-only proteins (BID, BIM, BAD, etc.)
  2. These activate BAX and BAK → oligomerize → pores in OMM → MOMP
  3. Cytochrome c is released from the IMS into the cytoplasm
  4. Cytochrome c + APAF-1 → forms the apoptosome
  5. Apoptosome activates Caspase-9 (initiator) → Caspase-3 and -7 (executioners) → cell death
• Anti-apoptotic proteins (BCL-2, BCL-XL, MCL-1) prevent cytochrome c release
• Venetoclax: BCL-2 inhibitor used in CLL and AML
• Other mitochondrial proteins released: Smac/DIABLO (inhibits IAPs), AIF (caspase-independent death), endonuclease G, Omi/HtrA2

10.3 Cytochrome c in Evolution

• One of the most conserved proteins in evolution — used to construct phylogenetic trees
• Human and chimpanzee cytochrome c are identical (100% homology)
• Human and yeast share ~60% identity

---

11. COMPLEX IV — CYTOCHROME c OXIDASE (EC 1.9.3.1)

11.1 Structure

• ~200 kDa as a functional dimer (each monomer: 13 subunits in mammals)
• 3 mtDNA-encoded subunits: COX I, COX II, COX III (catalytic core)
• 10 nuclear-encoded subunits (regulatory/structural)
• Contains 4 redox-active metal centers:
  • CuA center (in COX II): dinuclear copper; first to accept electron from cytochrome c
  • Heme a (in COX I): transfers electron to the binuclear center
  • Heme a₃ (in COX I): part of the binuclear center
  • CuB (in COX I): part of the binuclear center; paired with heme a₃

11.2 Mechanism

1. Cytochrome c (reduced) binds to the IMS face → donates 1 electron to CuA
2. CuA → heme a → binuclear center (heme a₃–CuB)
3. At the binuclear center, O₂ binds between Fe of heme a₃ and CuB
4. Four electrons required to fully reduce O₂:

O₂ + 4 e⁻ + 4 H⁺ (matrix) → 2 H₂O

1. Carefully controlled sequence avoids release of partially reduced oxygen species

11.3 Proton Pumping

• 4 "chemical" protons: consumed in the matrix to make H₂O (scalar protons)
• 4 "pumped" protons: translocated from matrix to IMS (vectorial protons)
• Total: 8 H⁺ removed from the matrix per O₂

11.4 Overall Reaction

4 cyt c (red) + O₂ + 8H⁺(matrix) → 4 cyt c (ox) + 2H₂O + 4H⁺(IMS)

11.5 Inhibitors of Complex IV

🔴 CLINICAL: Cyanide Poisoning

• Sources: industrial chemicals (electroplating, mining), smoke inhalation (burning of plastics/wool/silk releases HCN), cyanogenic glycosides (bitter almonds, cassava, apple seeds — contain amygdalin), sodium nitroprusside (prolonged infusion)
• Mechanism: CN⁻ binds Fe³⁺ of cytochrome a₃ → complete inhibition of Complex IV → histotoxic/cytotoxic hypoxia
• Classic features:
  • Bright cherry-red skin (venous blood remains oxygenated — cells can't extract O₂)
  • "Bitter almond" breath odor (only 40% of people can detect this — genetically determined)
  • High venous PO₂ (narrow A-V O₂ difference)
  • Severe lactic acidosis
  • PaO₂ and O₂ saturation may be normal (pulse oximetry and ABG can be misleadingly normal)
• Treatment:
  • 100% oxygen
  • Hydroxocobalamin (Cyanokit®): binds CN⁻ → cyanocobalamin (B₁₂) → renal excretion. Preferred antidote (safe in combined CO/CN poisoning)
  • Sodium thiosulfate: sulfur donor for rhodanese → converts CN⁻ → thiocyanate (SCN⁻) → renal excretion. Slow onset.
  • Sodium nitrite / amyl nitrite: induces methemoglobinemia → MetHb (Fe³⁺) binds CN⁻. Caution in smoke inhalation (already has COHb)
  • Dicobalt edetate (Kelocyanor): used in UK — cobalt chelates CN⁻

🔴 CLINICAL: Carbon Monoxide (CO) Poisoning

• CO binds to:
  1. Hemoglobin (240× greater affinity than O₂) → carboxyhemoglobin (COHb) → leftward shift of O₂-Hb dissociation curve
  2. Cytochrome c oxidase (Complex IV) → Fe²⁺ of heme a₃ → histotoxic hypoxia
  3. Myoglobin → impaired muscle O₂ utilization
• Sources: incomplete combustion, house fires, car exhaust, charcoal grills
• Findings:
  • Headache (most common early symptom), nausea, confusion, syncope, seizures, coma
  • PaO₂ is NORMAL (dissolved O₂ unaffected)
  • O₂ saturation by pulse oximetry is FALSELY NORMAL (can't distinguish COHb from OxyHb)
  • CO-oximetry is the diagnostic test
  • Normal COHb <3% (non-smokers); symptomatic >15-20%; lethal >50-60%
• Treatment:
  • 100% O₂ via non-rebreather mask (reduces COHb half-life from 5 hours → 90 minutes)
  • Hyperbaric oxygen (HBO₂): reduces half-life to ~30 minutes; indicated for COHb >25%, loss of consciousness, neurological symptoms, cardiac ischemia, pregnancy

🔴 CLINICAL: Hydrogen Sulfide (H₂S) Poisoning

• "Knockdown gas" — toxic in sewer gas, volcanic emissions, petroleum industry
• Mechanism: like cyanide, inhibits Complex IV
• Rotten egg smell at low concentrations; at high concentrations → olfactory nerve paralysis (extremely dangerous — can no longer smell it)
• Treatment: nitrites (to form sulfmethemoglobin), 100% O₂, supportive

🔴 CLINICAL: Methanol and Formate Toxicity

• Methanol → formaldehyde → formic acid/formate (via alcohol dehydrogenase and aldehyde dehydrogenase)
• Formate inhibits cytochrome c oxidase (Complex IV)
• Causes: metabolic acidosis (high anion gap), blindness (retinal ganglion cell toxicity)
• Treatment: fomepizole (ADH inhibitor) or ethanol (competitive substrate), dialysis, folate

---

12. COMPLEX V — ATP SYNTHASE (F₁F₀-ATP SYNTHASE) (EC 7.1.2.2)

12.1 Overview

• Also called: F₁F₀-ATPase, Complex V
• Uses the proton motive force (PMF) generated by Complexes I, III, IV to synthesize ATP from ADP + Pi
• ~600 kDa
• 16 subunits in mammals (2 mtDNA-encoded: ATPase 6 = subunit a, ATPase 8 = subunit A6L)

12.2 Structure

F₁ Component (Soluble, Matrix side)

• Knob-like structure projecting into the matrix
• Composition: α₃β₃γδε
  • 3 α subunits and 3 β subunits: arranged alternately like segments of an orange
  • Each β subunit contains a catalytic site for ATP synthesis
  • The 3 β subunits exist in 3 different conformations simultaneously (see binding change mechanism)
  • γ subunit: central stalk/axle; rotates within the α₃β₃ ring; asymmetric → drives conformational changes in β subunits
  • ε subunit: attached to γ; part of the rotor
  • δ subunit (OSCP — Oligomycin Sensitivity Conferring Protein): part of the peripheral stalk

F₀ Component (Membrane-embedded)

• Proton channel driving rotation
• Composition (in mammals):
  • c-ring: ring of 8 c subunits in mammals (10 in yeast); each c subunit has a proton-binding carboxylate (Asp or Glu)
  • a subunit (subunit 6): has two half-channels for proton translocation; stationary
  • b subunit: part of the peripheral/lateral stalk (stator)
  • Additional subunits: d, F6, A6L, e, f, g (structural and regulatory)

Peripheral Stalk (Stator)

• Connects F₁ to F₀ without rotating
• Composed of: b, d, F6, OSCP subunits
• Prevents co-rotation of α₃β₃ with γ

12.3 Boyer's Binding Change Mechanism

Three Conformations of β Subunits:

1. O (Open): low affinity for substrates; releases ATP
2. L (Loose): binds ADP + Pi loosely
3. T (Tight): catalyzes ATP formation; binds ATP very tightly

Catalytic Cycle (per 120° rotation of γ):

• ADP + Pi bind to the L-site → γ rotates 120° → L-site converts to T-site → ATP is synthesized
• Previous T-site converts to O-site → ATP is released
• Previous O-site converts to L-site → ready for new ADP + Pi

12.4 Proton Translocation Through F₀

1. H⁺ from IMS enters the inlet half-channel in the a subunit
2. H⁺ binds to the carboxylate (Asp/Glu) on a c subunit
3. Neutralization allows the c subunit to move into the hydrophobic lipid bilayer
4. As the c-ring rotates (driven by the proton gradient), each c subunit eventually reaches the outlet half-channel on the matrix side
5. The H⁺ is released into the matrix

• In mammals (8 c subunits): 8 H⁺ per 360° → 8/3 ≈ 2.67 H⁺ per ATP
• Plus 1 H⁺ for the phosphate carrier (Pi/H⁺ symport) → ~3.67 H⁺ per ATP
• Often approximated as ~4 H⁺ per ATP

12.5 ATP/ADP Translocase (Adenine Nucleotide Translocator — ANT)

• Located in IMM
• Antiporter: exchanges ATP⁴⁻ (out to IMS) for ADP³⁻ (in to matrix)
• Electrogenic — driven by the membrane potential (Δψ)

🔴 CLINICAL: Bongkrekic Acid Poisoning

• From fermented coconut or corn products contaminated with Burkholderia gladioli pathovar cocovenenans
• Outbreaks in Southeast Asia, China
• Inhibits ANT → ATP depletion → multiorgan failure; very high mortality (40-100%)

12.6 Inhibitors of ATP Synthase (Complex V)

🔴 CLINICAL: ATP Synthase Deficiency

• Mutations in MT-ATP6 (subunit a):
  • NARP syndrome (Neuropathy, Ataxia, Retinitis Pigmentosa): mutant mtDNA load 70-90%
  • Maternally Inherited Leigh Syndrome (MILS): mutant load >90%
  • Most common mutation: m.8993T>G or m.8993T>C
• TMEM70 mutations: most common nuclear-encoded ATP synthase deficiency; 3-methylglutaconic aciduria, cardiomyopathy, lactic acidosis

---

13. THE PROTON MOTIVE FORCE (PMF)

13.1 Definition

• Δψ = membrane potential (voltage gradient) — inside (matrix) is negative; ~150-180 mV in mammals
• ΔpH = pH gradient — matrix is more alkaline (~0.5-1.0 pH units)
• Under physiological conditions: ~80% from Δψ, ~20% from ΔpH

13.2 Total Protons Pumped

---

14. CHEMIOSMOTIC HYPOTHESIS

Peter Mitchell (1961) — Nobel Prize in Chemistry (1978)

14.1 Key Postulates:

1. The ETC complexes are vectorially arranged in the IMM, pumping protons from matrix → IMS
2. The IMM is impermeable to protons — the proton gradient is maintained
3. The electrochemical proton gradient (PMF) stores energy
4. Protons flow back into the matrix only through ATP synthase → drives ATP synthesis
5. Electron transport and ATP synthesis are coupled through the PMF — not by chemical intermediates

14.2 Evidence Supporting the Hypothesis:

1. Intact IMM is required for oxidative phosphorylation
2. Uncouplers (which dissipate the proton gradient) abolish ATP synthesis without stopping electron transport
3. Artificially created pH gradients across vesicles can drive ATP synthesis
4. ATP synthase reconstituted in artificial liposomes produces ATP when a pH gradient is applied
5. Ionophores that collapse the gradient inhibit ATP synthesis

---

15. P/O RATIOS AND ATP YIELD

15.1 Definition

15.2 Revised Values (Current Consensus)

15.3 Total ATP Yield from Complete Oxidation of Glucose

• 8 mitochondrial NADH × 2.5 = 20 ATP
• 2 cytoplasmic NADH — yield depends on shuttle used (see Section 16)
• 2 FADH₂ × 1.5 = 3 ATP
• 4 ATP/GTP (substrate level)

---

16. SHUTTLE SYSTEMS

16.1 Malate-Aspartate Shuttle

1. Cytoplasmic OAA + NADH → malate + NAD⁺ (cytoplasmic malate dehydrogenase)
2. Malate crosses IMM via the malate-α-ketoglutarate antiporter
3. Matrix malate → OAA + NADH (mitochondrial malate dehydrogenase)
4. Matrix OAA → transaminated to aspartate (by aspartate aminotransferase, glutamate → α-KG)
5. Aspartate exits via the glutamate-aspartate antiporter (electrogenic — driven by Δψ)
6. Cytoplasmic aspartate → OAA (by cytoplasmic aspartate aminotransferase)
7. α-KG returns to matrix via malate-αKG antiporter

16.2 Glycerol-3-Phosphate Shuttle

1. Cytoplasmic DHAP + NADH → glycerol-3-phosphate + NAD⁺ (cytoplasmic G3P dehydrogenase — NAD⁺-linked)
2. G3P → DHAP + FADH₂ (mitochondrial G3P dehydrogenase — FAD-linked, on outer surface of IMM)
3. FADH₂ directly reduces CoQ in the IMM

🔴 CLINICAL: Malate-Aspartate Shuttle and Aralar1/AGC1 Deficiency

• SLC25A12 mutations (AGC1/Aralar1 — mitochondrial aspartate-glutamate carrier)
• Causes global cerebral hypomyelination, developmental delay, seizures

---

17. INHIBITORS OF THE ETC — COMPREHENSIVE SUMMARY

17.1 Classification by Site

17.2 Effects of ETC Inhibitors

1. Upstream of the block: carriers become more reduced
2. Downstream of the block: carriers become more oxidized
3. O₂ consumption decreases
4. ATP synthesis decreases
5. NADH/NAD⁺ ratio increases → inhibits TCA cycle
6. Lactic acidosis

---

18. UNCOUPLERS OF OXIDATIVE PHOSPHORYLATION

18.1 Definition

18.2 Mechanism

1. Pick up H⁺ on the IMS side (protonated form is lipid-soluble)
2. Cross the IMM in their protonated form
3. Release H⁺ on the matrix side
4. Return in their anionic form
5. Short-circuits the proton gradient → collapses Δp

18.3 Effects of Uncoupling

18.4 Examples of Uncouplers

🔴 CLINICAL: 2,4-Dinitrophenol (DNP) Toxicity

• Used in the 1930s as a weight-loss agent — uncoupling → increased metabolic rate → fat burning
• Banned by FDA in 1938; still available illegally online
• Symptoms: profuse sweating, tachycardia, tachypnea, hyperthermia (potentially fatal)
• Cataracts with chronic use
• No specific antidote — supportive: cooling, dantrolene may help
• Narrow therapeutic index → small dose increase can be lethal

🔴 CLINICAL: Aspirin (Salicylate) Overdose

• High-dose salicylates:
  1. Uncouple oxidative phosphorylation (weak acid, lipid-soluble)
  2. Direct stimulant of the respiratory center (medullary)
• Clinical toxicity:
  • Respiratory alkalosis (early — direct stimulation of respiratory center)
  • Metabolic acidosis (high anion gap — from uncoupling → lactate, ketoacids + salicylate itself)
  • Mixed respiratory alkalosis and metabolic acidosis is characteristic
  • Hyperthermia, tinnitus, diaphoresis, nausea/vomiting
• Treatment: sodium bicarbonate (alkalinize urine → traps salicylate in ionized form), hemodialysis for severe cases, cooling

18.5 Thermogenin (UCP1) and Brown Adipose Tissue (BAT)

🔴 CLINICAL: Non-Shivering Thermogenesis

• Brown adipose tissue (BAT) — abundant mitochondria (brown color from cytochromes)
• Contains UCP1 (Uncoupling Protein 1 / Thermogenin) — a natural proton channel in the IMM
• UCP1 allows H⁺ to re-enter the matrix without passing through ATP synthase → energy released as HEAT
• Important in:
  • Neonates (who cannot shiver) — major source of heat production
  • Hibernating animals
  • Adults (metabolically active BAT in supraclavicular, paravertebral, perirenal regions)
• Regulation of UCP1:
  • Activated by: free fatty acids, norepinephrine (via β₃-adrenergic receptors → cAMP → PKA → hormone-sensitive lipase → FFA release → FFA activates UCP1)
  • Inhibited by: purine nucleotides (GDP, GTP, ADP, ATP) — bind and block the channel
• Thyroid hormones (T₃) upregulate UCP1 → explains heat intolerance in hyperthyroidism

18.6 Other Uncoupling Proteins

---

19. TIGHT COUPLING, RESPIRATORY CONTROL, AND REGULATION

19.1 Respiratory Control

• The rate of O₂ consumption (electron transport) is determined by the availability of ADP
• Low ADP → no ATP synthesis needed → proton gradient builds up → back-pressure inhibits ETC → O₂ consumption decreases (State 4)
• High ADP → ADP enters mitochondria → ATP synthase active → proton gradient consumed → ETC speeds up → O₂ consumption increases (State 3)

19.2 Respiratory States (Chance & Williams)

• Respiratory Control Ratio (RCR) = State 3 rate / State 4 rate
• Normal RCR = 5-10 (tight coupling); low RCR = uncoupling or damaged mitochondria

19.3 Regulation of ETC

---

20. REACTIVE OXYGEN SPECIES (ROS)

20.1 Overview

20.2 Sites of ROS Production

20.3 Types of ROS

20.4 Antioxidant Defense Systems

20.5 ROS-Mediated Damage

🔴 CLINICAL: ROS and Disease

• Aging: cumulative mtDNA damage → declining ETC function → more ROS → more damage (vicious cycle) — "Mitochondrial free radical theory of aging"
• Ischemia-Reperfusion Injury: reperfusion → massive ROS burst from dysfunctional ETC (relevant in MI, stroke, organ transplantation)
• Neurodegenerative diseases: Parkinson's (Complex I deficiency, ROS in substantia nigra), Alzheimer's, ALS
• Diabetes: hyperglycemia → increased ETC substrate → ROS overproduction → diabetic complications

🔴 CLINICAL: Superoxide Dismutase and ALS

• ~20% of familial ALS cases involve mutations in SOD1 (Cu/ZnSOD)
• Gain of toxic function (misfolded SOD1 aggregates → motor neuron death) — NOT loss-of-function
• Autosomal dominant

🔴 CLINICAL: Friedreich's Ataxia and Iron-Sulfur Clusters

• Autosomal recessive; most common hereditary ataxia
• GAA trinucleotide repeat expansion in FXN gene (frataxin)
• Frataxin → involved in iron-sulfur cluster assembly and iron homeostasis
• Frataxin deficiency → impaired Fe-S cluster synthesis → dysfunctional Complexes I, II, III and aconitase
• Mitochondrial iron accumulation → Fenton reaction → ROS damage
• Clinical: progressive gait and limb ataxia, dysarthria, hypertrophic cardiomyopathy (major cause of death), diabetes mellitus, absent deep tendon reflexes, pes cavus, scoliosis, upgoing plantars
• Treatment: omaveloxolone (Nrf2 activator — FDA approved 2023), idebenone (limited benefit)

---

21. SUPERCOMPLEXES (RESPIRASOMES)

21.1 Concept

21.2 Functional Significance

• Substrate channeling: CoQ and cytochrome c channeled between complexes → faster electron transfer
• Reduced ROS: shorter transit time → less chance of electron leak to O₂
• Stabilization: Complex I is unstable without Complex III
• Cardiolipin is essential for supercomplex assembly

🔴 CLINICAL: Supercomplex Dysfunction

• Heart failure: decreased supercomplex assembly → increased ROS, decreased ATP production
• Barth syndrome: cardiolipin deficiency → impaired supercomplex formation
• Aging: decreased supercomplex levels in aged tissues

---

22. COMPREHENSIVE CLINICAL CORRELATIONS

22.1 Mitochondrial Diseases — Overview

• Brain: encephalopathy, seizures, stroke-like episodes, ataxia
• Muscle: myopathy, exercise intolerance, ophthalmoplegia
• Heart: cardiomyopathy, conduction defects
• Eye: optic neuropathy, retinitis pigmentosa, ptosis
• Ear: sensorineural hearing loss
• Endocrine: diabetes mellitus, growth hormone deficiency
• GI: pseudo-obstruction
• Kidney: tubular dysfunction, Fanconi syndrome

• Elevated serum lactate (most consistent finding)
• Elevated lactate:pyruvate ratio (>20:1)
• Elevated alanine
• Ragged red fibers (RRF) on Gomori trichrome stain of muscle biopsy
• COX-negative fibers on cytochrome c oxidase staining
• MRI: stroke-like lesions not conforming to vascular territories, bilateral basal ganglia lesions (Leigh syndrome), cerebellar atrophy

22.2 Specific Mitochondrial Syndromes

MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like episodes)

• Mutation: m.3243A>G in MT-TL1 (tRNA^Leu(UUR)) — ~80% of cases
• Features: stroke-like episodes (NOT true strokes — don't follow vascular territories; often occipital/parietal), lactic acidosis, seizures, myopathy, sensorineural hearing loss, diabetes mellitus (MIDD — maternally inherited diabetes and deafness), short stature, migraine, cognitive decline, ragged red fibers

MERRF (Myoclonic Epilepsy with Ragged Red Fibers)

• Mutation: m.8344A>G in MT-TK (tRNA^Lys) — ~80% of cases
• Features: myoclonus (stimulus-sensitive), generalized epilepsy, myopathy with RRF, cerebellar ataxia, multiple symmetric lipomas (especially cervical), sensorineural hearing loss, optic atrophy, dementia, lactic acidosis

Leigh Syndrome (Subacute Necrotizing Encephalomyelopathy)

• Most common mitochondrial disease in infancy/childhood
• Caused by mutations in >75 different genes (both mtDNA and nuclear)
  • Complex I (most common), Complex II, Complex III, Complex IV, Complex V, PDH, CoQ₁₀ biosynthesis
  • Common: MT-ATP6 (m.8993T>G/C), SURF1 (Complex IV assembly), NDUFS4 (Complex I)
• Pathology: bilateral, symmetric necrotizing lesions in basal ganglia, brainstem, thalamus, spinal cord
• Features: developmental regression, hypotonia → spasticity, respiratory abnormalities (central hypoventilation), eye movement abnormalities, lactic acidosis
• MRI: bilateral symmetric T2-hyperintense lesions in basal ganglia and brainstem

Kearns-Sayre Syndrome (KSS)

• Large-scale mtDNA deletions (most common: "common deletion" — 4,977 bp); usually sporadic
• Diagnostic triad (ALL required):
  1. Progressive External Ophthalmoplegia (PEO) — ptosis + restricted eye movements
  2. Pigmentary retinopathy ("salt and pepper" fundus)
  3. Onset before age 20
• Plus at least one of: cardiac conduction defect, cerebellar ataxia, CSF protein >100 mg/dL
• Other features: short stature, hearing loss, endocrinopathies, cognitive decline
• Cardiac conduction defects are life-threatening → may require pacemaker
• Ragged red fibers and COX-negative fibers on muscle biopsy

Pearson Syndrome

• Same large-scale mtDNA deletions as KSS; presents in infancy
• Sideroblastic anemia + pancreatic exocrine insufficiency
• Bone marrow: vacuolization of precursors, ringed sideroblasts
• Survivors may develop KSS in later years

NARP (Neuropathy, Ataxia, Retinitis Pigmentosa)

• Mutation: m.8993T>G (or T>C) in MT-ATP6
• Heteroplasmy level 70-90% → NARP; >90% → Leigh syndrome (MILS)
• Features: peripheral neuropathy, cerebellar ataxia, retinitis pigmentosa, proximal weakness, developmental delay

Aminoglycoside-Induced Ototoxicity

• Mutation: m.1555A>G in MT-RNR1 (12S rRNA)
• Makes mitochondrial ribosome more "bacterial-like" → aminoglycosides damage mitochondrial translation
• Even a single dose of aminoglycosides → permanent bilateral sensorineural hearing loss

🔴 CLINICAL: POLG Mutations

• POLG encodes mitochondrial DNA polymerase γ (responsible for mtDNA replication)
• Wide spectrum:
  • Alpers-Huttenlocher syndrome: progressive encephalopathy, intractable seizures, hepatopathy → liver failure (VALPROATE IS CONTRAINDICATED in POLG mutations — precipitates fatal hepatotoxicity)
  • CPEO (with multiple mtDNA deletions)
  • Ataxia-neuropathy spectrum (MIRAS, SANDO)

22.3 Acquired Conditions Affecting the ETC

Ischemia-Reperfusion Injury

• Ischemia: O₂ deprivation → ETC stops → succinate accumulates → ATP depleted → anaerobic glycolysis → acidosis → Ca²⁺ accumulation
• Reperfusion: O₂ reintroduced → accumulated succinate rapidly oxidized by Complex II → reverse electron transport (RET) through Complex I → massive superoxide production → oxidative damage
• Clinical: MI reperfusion, stroke thrombolysis, organ transplantation

Drug-Induced Mitochondrial Toxicity

Malignant Hyperthermia

🔴 CLINICAL: Malignant Hyperthermia

• Autosomal dominant; mutations in RYR1 (Ryanodine Receptor 1) — ~70% — or CACNA1S
• Triggered by volatile anesthetics (halothane, sevoflurane, desflurane, isoflurane) and/or succinylcholine
• Mechanism: uncontrolled Ca²⁺ release from SR → sustained muscle contraction → massively increased ATP consumption → accelerated ETC → excessive heat production
• Features: rapidly rising temperature, muscle rigidity (masseter/jaw rigidity is early sign), tachycardia, hypercarbia, metabolic acidosis, rhabdomyolysis, hyperkalemia
• Treatment: dantrolene (blocks RyR1 Ca²⁺ release), active cooling, treat hyperkalemia and acidosis

22.4 Thyroid Hormones and ETC

• Hyperthyroidism: increased ETC expression + increased UCP expression → increased O₂ consumption, heat production → heat intolerance, weight loss, sweating, tachycardia, increased BMR
• Hypothyroidism: decreased ETC activity → cold intolerance, weight gain, fatigue, decreased BMR

---

23. SUMMARY TABLES

Table 1: Complete Summary of ETC Complexes

Table 2: Proton Accounting

Table 3: ATP Yield

Table 4: Vitamins and Minerals in ETC

Table 5: Inhibitors vs. Uncouplers

Table 6: Mitochondrial Syndromes Quick Reference

---

FINAL INTEGRATIVE SUMMARY

• Inhibition (at any complex — leading to electron transport cessation, ATP depletion, and lactic acidosis)
• Uncoupling (dissipation of the proton gradient — electron transport continues but ATP is not made; energy is released as heat)
• Genetic disorders (mutations in either mtDNA or nuclear genes encoding ETC subunits, assembly factors, or mtDNA maintenance proteins — producing a vast spectrum of multisystem diseases preferentially affecting high-energy tissues)

1. Section 1 - Full ETC schematic with all 5 complexes in the inner mitochondrial membrane
2. Section 2 - Detailed diagram showing all five complexes with NADH/FADH₂ entry points, CoQ and cytochrome c as mobile carriers, and electron flow to O₂
3. Section 4 - Simplified ETC diagram showing the three energy-drop sites (Complexes I, III, IV) and proton pumping
4. Section 9 - Wikipedia Q Cycle diagram showing Complex III, the Qo/Qp and Qi/Qn sites, electron bifurcation, and proton release
5. Section 12 - F₁F₀ ATP synthase structure with the rotary mechanism clearly labeled
6. Section 12 (also) - Boyer's binding change mechanism showing the three β-subunit conformations (O, L, T)
7. Section 13 - Complete ETC + ATP synthase overview showing proton accounting
8. Final Summary - Full ETC diagram as an integrative closing image